

Integrator complex subunit 12 knockout overcomes a transcriptional block to HIV latency reversal

Carley N Gray, Manickam Ashokkumar, Derek H Janssens, Jennifer Kirchherr, Brigitte Allard, Emily Hsieh, Terry L Hafer, Nancie M Archin, Edward P Browne, Michael Emerman 

Department of Microbiology, University of Washington, Seattle, United States • Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States • UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, United States • Division of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, United States • Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, United States • Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, United States • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, United States

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

 A newer version is available. [Read the latest version.](#)

Version of Record

April 10, 2025

Reviewed Preprint

v2 • March 26, 2025

Revised by authors

Reviewed Preprint

v1 • November 21, 2024

eLife Assessment

Using multiple techniques previously validated by the authors, this study identified INTS12, a component of the Integrator complex involved in 3' processing of small nuclear RNAs U1 and U2, as a factor promoting HIV-1 latency. The work is **valuable**, based on a sound strategy for screening targets to activate HIV latency and the **solid** mechanistic insights it provides on INTS12 repression of transcriptional elongation. Future studies are needed to explore INTS12 as a drug target against HIV/AIDS.

<https://doi.org/10.7554/eLife.103064.2.sa4>

Abstract

The latent HIV reservoir is a major barrier to HIV cure. Combining latency reversal agents (LRAs) with differing mechanisms of action such as AZD5582, a non-canonical NF- κ B activator, and I-BET151, a bromodomain inhibitor is appealing towards inducing HIV-1 reactivation. However, even this LRA combination needs improvement as it is inefficient at activating proviruses in cells from people living with HIV (PLWH). We performed a CRISPR screen in conjunction with AZD5582 & I-BET151 and identified a member of the Integrator complex as a target to improve this LRA combination, specifically Integrator complex subunit 12 (INTS12). Integrator functions as a genome-wide attenuator of transcription that acts on elongation through its RNA cleavage and phosphatase modules. Knockout of INTS12 improved latency reactivation at the transcriptional level and is more specific to the HIV-1 provirus than AZD5582 & I-BET151 treatment alone. We found that INTS12 is present on chromatin at the promoter of HIV and therefore its effect on HIV may be direct. Additionally, we observed more RNAPII in the gene body of HIV only with the combination of INTS12 knockout with AZD5582 & I-BET151, indicating that INTS12 induces a transcriptional elongation block to viral reactivation. Moreover, knockout of INTS12 increased HIV-1

reactivation in CD4 T cells from virally suppressed PLWH *ex vivo*, and we detected viral RNA in the supernatant from CD4 T cells of all three virally suppressed PLWH tested upon INTS12 knockout suggesting that INTS12 prevents full-length HIV RNA production in primary T cells. Finally, we found that INTS12 more generally limits the efficacy of a variety of LRAs with different mechanisms of action.

Introduction

Despite advancements in keeping viral loads below detectable limits, HIV-1 still exists within a latent reservoir *in vivo* and viral replication returns when anti-retroviral therapy (ART) is interrupted (Davey et al., 1999 [DOI](#)). HIV-1 predominately infects memory CD4⁺ T cells (reviewed in (Ait-Ammar et al., 2019 [DOI](#); Cohn et al., 2020 [DOI](#))) and while many acutely infected cells, particularly the more differentiated effector memory cells, die off rapidly upon infection due to cytopathic effects, some cells can revert to a resting state where the provirus becomes transcriptionally silent (reviewed in (Duggan et al., 2023 [DOI](#); Mbonye & Karn, 2024 [DOI](#))). These infected resting memory cells form the HIV reservoir that is largely invisible to the immune system and not sensitive to enhanced antiviral therapy (Siliciano & Siliciano, 2024 [DOI](#)). The reservoir of latently infected cells decays slowly and is maintained by both external stimuli and homeostatic proliferation even after initiation of ART (reviewed in (Cohn et al., 2020 [DOI](#))). Thus, the major barrier to HIV cure is the existence of this ART-insensitive and long-lived latent reservoir that is largely not sensed by the immune system (Chun & Fauci, 1999 [DOI](#)), reviewed in (Duggan et al., 2023 [DOI](#); Mbonye & Karn, 2024 [DOI](#))).

One strategy being explored to target the latent reservoir, called “shock-and-kill”, uses small molecule compounds called latency reversal agents (LRAs) to transcriptionally activate latent cells, so that immune-mediated mechanisms can then recognize and kill infected cells (Archin et al., 2012 [DOI](#)), reviewed in (Maina et al., 2021 [DOI](#))). This strategy would be employed in the presence of ART so that newly induced HIV virions could not infect more cells. However, inducing HIV-1 activation from latency is challenging, because the latent reservoir size varies between people and heterogeneous HIV integration sites can influence reactivation of infected cells (reviewed in (Ait-Ammar et al., 2019 [DOI](#))). Moreover, activation of latently infected resting T cells has not yet been able to induce HIV-1 replication from more than a fraction of the cells with a replication-competent provirus (Ho et al., 2013 [DOI](#); Siliciano & Siliciano, 2024 [DOI](#))).

Transcriptional repression of HIV-1 in its latent state is multifactorial and it is known to be affected by repressive chromatin modifications and blocks to both transcription initiation and transcription elongation. Several classes of LRAs have been identified that can undo one or more blocks to latency reversal (Stoszek et al., 2019 [DOI](#)), reviewed in (Rodari et al., 2021 [DOI](#); Singh et al., 2021 [DOI](#))). For example, AZD5582 is an LRA that targets a transcription initiation block by activating the noncanonical NF-κB pathway (Hennessy et al., 2013 [DOI](#); Pache et al., 2020 [DOI](#)) and has been shown to induce HIV transcription in HIV latency cell line models as well as induce viremia in animal models (Nixon et al., 2020 [DOI](#))).

Another class of LRAs are BET inhibitors that undo a block to transcription elongation by targeting various bromodomain containing proteins. I-BET151 is a pan-BET inhibitor that is thought to reverse HIV latency by either blocking host Brd4 from binding to PTEF-b to facilitate PTEF-b availability for HIV Tat (Jang et al., 2005 [DOI](#); Schroder et al., 2012 [DOI](#); Yang et al., 2005 [DOI](#)) or more generally by increasing the amount of PTEF-b not bound to the 7SK complex (Turner, 2024). Currently, no single LRA has been potent enough to reactivate the majority of the latent proviruses nor specific enough to HIV to not cause toxicity to the host (reviewed in (Debrabander et al., 2023 [DOI](#))). On the other hand, combinations of LRAs with different mechanisms of action have

shown synergy in HIV latency reversal in different model systems including the combination of AZD5582 & I-BET151 (Dai et al., 2022 [↗](#); Falcinelli et al., 2022 [↗](#); Laird et al., 2015 [↗](#)) reviewed in (Rodari et al., 2021 [↗](#)).

While the combination of AZD5582 & I-BET151 is synergistic in activation of HIV in latency cell line models, and can induce robust HIV transcription initiation *ex vivo* in primary CD4⁺ T cells from virally suppressed PLWH, it failed to induce full-length proviral transcription in the *ex vivo* system (Falcinelli et al., 2022 [↗](#)). Thus, there exist additional blocks to HIV reactivation that even potent LRA combinations currently cannot overcome.

Here we hypothesized that we could use a CRISPR screen to uncover pathways to improve LRA combinations. Previous work from our lab showed that we could use a high throughput CRISPR screening approach, called the Latency HIV-CRISPR screen, to predict gene knockouts that improve the efficacy of a single LRA, AZD5582. Specifically, knockout of ING3, a member of the NuA4 histone acetylation complex, could improve the potency and the specificity of AZD5582, both in J-Lat model systems and in a primary T cell model of latency. Thus, in this study, we used a similar strategy to identify gene knockouts to increase HIV latency reversal with the more powerful AZD5582 & I-BET151 drug combination, and uncovered Integrator complex subunit 12, INTS12, as contributing to a block in HIV reactivation, both on its own, but, especially in the presence of the AZD5582 & I-BET151 drug combination.

INTS12 is a subunit of the Integrator complex that is thought to act as a reader to link the complex to chromatin (Welsh & Gardini, 2023 [↗](#)). The Integrator Complex functions as a genome-wide attenuator of mRNA transcription where it can antagonize transcription with both its cleavage and phosphatase modules (Hu et al., 2023 [↗](#)), and members of Integrator have been shown to modulate transcription at the HIV LTR previously (Lykke-Andersen et al., 2021 [↗](#); Stadlmayer et al., 2014 [↗](#)).

We found that knocking out INTS12 reactivates HIV on its own and improves reactivation with AZD5582 & I-BET151 treatment. RNA-seq analysis showed that INTS12 knockout (KO) more specifically reactivates HIV compared to AZD5582 & I-BET151 treatment alone and the combination of INTS12 KO with AZD5582 & I-BET151 increases the potency of reactivation. Additionally, we have evidence of an elongation block being overcome with INTS12 KO paired with AZD5582 & I-BET151 specifically showing an increase in bound elongation-competent RNAPII in the gene body of HIV that is not seen with either KO or LRA treatment alone. We found that INTS12 is bound to the viral promoter and therefore may be acting directly on viral transcription. Importantly, we saw reactivation of HIV in the CD4 T cells of the majority of the virally suppressed people living with HIV (PLWH) tested *ex-vivo*, upon INTS12 KO with or without AZD5582 & I-BET151 treatment. Crucially, we also detected viral RNA in the supernatant suggestive of the presence of HIV virions released into the supernatant indicating that full length HIV transcripts are being generated. Furthermore, we used the HIV-CRISPR screen approach to probe the Integrator complex as a whole and predict Integrator members comprising the cleavage module, phosphatase module, and core to all be involved in the control of HIV-1 latency in addition to the reader, INTS12. Lastly, we show that knockout of INTS12 can increase reactivation with diverse classes of LRAs suggesting that INTS12 is a general block to HIV reactivation.

Results

Latency HIV-CRISPR screen identifies gene targets that increase HIV latency reversal with AZD5582 & I-BET151 treatment

We used a high throughput CRISPR screen previously described by our lab (Hsieh et al., 2023 [DOI](#)) to identify gene targets that, when knocked out, would further improve latency reversal agents. The screen involves a lentiviral vector, called HIV-CRISPR, that contains two functional LTRs, a packaging signal, a guide RNA, and Cas9 to knock out a gene of interest (**Figure 1A** [DOI](#)). Cells that have a latent HIV provirus are transduced with a library of HIV-CRISPR-containing guides and then, after selection for integration of the vector, the cells are treated with the combination of LRAs, AZD5582 & I-BET151 to reactivate HIV (**Figure 1A** [DOI](#)). If a gene knockout improves LRA reactivation, we will detect more HIV in the supernatant compared to the DMSO control. We can determine the gene knockout responsible for HIV reactivation because the HIV-CRISPR vector will be packaged along with the reactivated provirus from the cells and become enriched in the supernatant (**Figure 1A** [DOI](#), see purple or black HIV RNA in virions). We then determine how enriched a guide is by the ratio of guides in the supernatant compared to the total guide representation in the cells and this generates a value called the MAGECK gene score, where higher values correspond to more enrichment (i.e. HIV reactivation) (Li et al., 2014 [DOI](#)). Importantly, all guides to one gene target and replicates are factored into the MAGECK gene score generation.

We used a custom human epigenome guide library (HuEpi library) that contains 5,309 sgRNAs total (839 genes with 6 guides/gene) that comprises histone binders/modifiers and other general chromatin-associated proteins, which casts a wide net on general epigenetic factors (further description of this library and the major gene ontology categories targeted has been published (Hsieh et al., 2023 [DOI](#)). We previously validated the HuEpi library as containing guides to multiple genes involved in HIV-1 latency (Hsieh et al., 2023 [DOI](#)). Here, we conducted additional screens in two cell lines, J-Lat 10.6 and J-Lat 5A8, that are clonal Jurkat T-lymphocyte cell lines that contain latent HIV. We chose these cells because they differ in integration site and HIV drug reactivation profiles (Chan et al., 2013 [DOI](#); Jordan et al., 2003 [DOI](#); Spina et al., 2013 [DOI](#); Telwatte et al., 2019 [DOI](#)), and wanted to identify commonly enriched genes that were not integration site specific.

The screen results are shown as a comparison of a DMSO-treated screen compared to a screen carried out in the presence of 10nM AZD5582 & 100nM I-BET151 combined (**Figure 1B** [DOI](#) and **C** [DOI](#)). Candidate knockouts that are predicted to improve the AZD5582 & I-BET151 combination specifically should fall above the dotted line in **Figure 1B** [DOI](#) and **1C** [DOI](#), as these genes are more highly enriched in the AZD5582 & I-BET151 screen compared to the DMSO screen. Genes that fall on the line are predicted to be drug-independent hits as they are equally enriched in both screens, and genes falling below the line are thought to be redundant to the function of the LRAs.

With this approach, we identified gene hits that have been validated previously using the same HuEpi library (Hsieh et al., 2023 [DOI](#)): KAT5, CUL3, ACTL6A, TAF5, DNMT1, DMAP1, VPS72, YEATS4, SRCAP, and ING3 (**Figure 1B** [DOI](#) and **C** [DOI](#), full screen list and results in supplemental file S1). Knockout of ING3 was previously shown to improve AZD5582 treatment for activation of latent HIV-1 (Hsieh et al., 2023 [DOI](#)), and also shows up as a candidate hit in the present screen done the presence of both AZD5582 & I-BET151 (**Figure 1B** [DOI](#) and **C** [DOI](#)). Our top hit, INTS12, here was also seen in our previous study (Hsieh et al., 2023 [DOI](#)), but was not followed up on in that study.

New gene hits of interest that we identified that are predicted to improve the AZD5582 & I-BET151 combination specifically in both J-Lat lines tested including (shown in blue or purple, **Fig. 1B** [DOI](#) and **1C** [DOI](#)): INTS12, TRRAP, RNF20, BRD2, TAF3, TAF4, UBE2D3, and UBE2H. Some hits, EZH2 and PPP2CA, were only predicted to improve AZD5582 & I-BET151 treatment in one cell line. Because EZH2 has a number of available inhibitors, we validated the screen with the EZH2 inhibitor Tazemetostat (Straining & Eighmy, 2022 [DOI](#)). That is, the screen predicted that inhibition of EZH2 would increase the potency of AZD5582 & I-BET151 to activate HIV-1 from latency in J-Lat 5A8 cells. Indeed, we found that Tazemetostat increases reactivation of HIV-1 in the presence of




Figure 1

A screen to predict gene knockouts that will improve HIV reactivation from the combination of AZD5582 & I-BET151.

(A) Basal J-Lat conditions (left panel) followed by screen scenarios (middle to right panels). Screen overview: J-Lat cells containing an internal provirus are transduced with the HIV-CRISPR vector to generate a library of knockout cells for the human epigenetic library. Knockout cells are selected by puromycin and then either treated with LRAs or untreated. The HIV-CRISPR vector is packageable and will accumulate in the supernatant if the internal HIV provirus is reactivated. Sequencing the supernatant and cells allows for measurement of how enriched a guide is. (A, from left to right) Basal conditions show a gene product can block reactivation of HIV at the transcriptional level. Knockout alone shows that upon introducing the HIV-CRISPR some gene knockouts will result in latency reversal in the absence of LRA treatment. LRA combo alone shows the effect of LRA stimulation alone and how this will result in non-targeting guides (black) accumulating in the supernatant. Knockout + LRA combo shows that some gene knockouts will improve reactivation with LRA treatment and result in more virus accumulation. B-C are the results of the screens in J-Lat 5A8 (B) and J-Lat 10.6 (C). Each are graphed as a comparison of the LRA combination AZD5582 & I-BET151 (Y-axis) treated screens to the untreated (DMSO) screens (X axis) as the -Log₂ MAgECK gene scores for each gene target. Purple and blue genes are genes in common between J-Lat 10.6 and 5A8 that are predicted to improve AZD5582 & I-BET151 treatment specifically and purple is the top gene hit in common. NTC = nontargeting control guide.

AZD5582 & I-BET151 to much higher levels than AZD5582 & I-BET151 alone or Tzaemetostat alone (**Figure 1**—figure supplement 1). However, we focused the remainder of this study on the most top ranking hit common to both J-Lat models that was enriched in the combination AZD5582 and I-BET151 treatment, Integrator Complex Subunit 12 (INTS12).

Integrator complex subunit 12 knockout specifically reactivates HIV independently and in combination with AZD5582 & I-BET151 treatment

The Integrator complex is known to play a role in the negative regulation of elongating transcripts (Elrod et al., 2019; Tatomer et al., 2019). Moreover, previous studies have shown that some Integrator members are recruited to the HIV LTR and regulate HIV transcript length (Stadelmayer et al., 2014), although INTS12 had not been previously implicated in HIV regulation. We validated INTS12 as a screen hit by either knocking out INTS12 with the HIV-CRISPR vector loaded with one guide and then selecting for knockout cells with puromycin (J-Lat 5A8 **Figure 2A**, J-Lat 10.6 (**Figure 2**—figure supplement 1) or by electroporation with a combination of three of guides to INTS12 (**Figure 2B** and **C**). We used AAVS1 knockout as a CRISPR control where the guide targets within a safe harbor locus and knockout should have a minimal effect on transcription (Li et al., 2014). These knockouts were then treated with DMSO, a low dose of AZD5582 (10nM), a low dose of I-BET151 (100nM), or a combination of AZD5582 (10nM) & I-BET151 (100nM) (**Figure 2A** and **B**) and the amount of HIV-1 released into the supernatant was measured by a reverse transcriptase activity assay (Vermeire et al., 2012). As expected, we find in AAVS1 knockout cells that there is minimal reactivation in the DMSO control, a small amount of HIV induction from AZD5582 or I-BET151 alone, and we observe synergy with AZD5582 & I-BET151 used in combination (**Figure 2A** and **B**). Knocking out INTS12 alone in the absence of added LRAs also shows a modest increase in the amount of virus detected in the supernatant (**Figure 2A** and **B**, DMSO), indicating that INTS12 itself is imposing a block to reactivation that is relieved upon knockout. In the presence of drug treatments, INTS12 knockout improves reactivation of either AZD5582 or I-BET151 alone and we see the most HIV reactivation when INTS12 knockout is treated with AZD5582 & I-BET151 in combination (**Figure 2A** and **B**), as the screen predicted (**Figure 1B** and **C**). Flow cytometry data using the expression of GFP in the provirus gave similar results and showed a greater percentage of cells are activated from INTS12 KO alone and in combination with AZD5582 & I-BET151 (**Figure 2**—figure supplement 2A and B S3). To ensure cell viability did not contribute to this phenotype, we measured cell proliferation in our AAVS1 KO and INTS12 KO cells overtime and we observed no differences in cell growth (**Figure 2**—figure supplement 3).

Furthermore, to ensure that this effect was due to knockout of INTS12 and not an off-target CRISPR effect, we performed INTS12 complementation experiments. We took pooled INTS12 KO cells and AAVS1 KO cells and transduced them with a lentiviral vector containing INTS12 and a puromycin resistance gene, selected for vector transduction, and then measured HIV reactivation (**Figure 2C**). We found that reactivation of the HIV-1 provirus in the INTS12 KO cells that were complemented with an INTS12 expression vector were now equivalent to the control AAVS1 KO cells with the same INTS12 expression vector (**Figure 2C**). These results show that INTS12 is responsible for a negative effect on HIV expression in the presence of latency reversal agents, AZD5582 and I-BET151.

INTS12 knockout increases HIV steady-state RNA levels with specificity for the LTR

To test the effects of INTS12 knockout on both HIV-1 and total host transcription, we performed RNA-seq on total RNA that has been ribosomal RNA depleted. RNA-seq was done on pooled INTS12 knockouts and pooled AAVS1 knockouts (as controls) in J-Lat 10.6 cells in biological triplicates, where knockout out of cells were generated three separate times and treated with either DMSO or




Figure 2

Validation of INTS12 knockout in HIV latency reversal both on its own and in the presence of AZD5582 & I-BET151.

J-Lat 5A8 (**A**) and J-Lat 10.6 (**B**) cells were knocked out for INTS12 or control locus, AAVS1. With a calculated INTS12 knockout score of 76% (for the one guide used) and 69% (for one of three guides used), respectively. Cells were then treated with 10 nM AZD5582 and or 100 nM I-BET151 for 48 hours (or an equivalent volume of DMSO), and HIV reverse transcriptase activity was measured from the supernatant (reported in mU/mL). (**C**) Complementation of cells knocked out for INTS12 or AAVS1 were transduced with a vector containing INTS12 before LRA treatments. These cells had an INTS12 knockout score of 55% for one of three guides used. Untreated = DMSO, AZD = AZD5582, IBET = I-BET151. For statistical analysis, all conditions are compared to the AAVS1 control. 2-way ANOVA, (**A-B**) uncorrected Fisher's LSD (**C**), Šídák's multiple comparisons test, p-value = <0.05 = *, = <0.01 = **, = <0.001 = ***, = <0.0001 = ****.

AZD5582 & I-BET151. We first looked at how the sum of all transcripts mapping to HIV changed with the different conditions (**Figure 3A** [↗](#)). We observed that the RNA-seq trend matches what we saw with the virus release assay (**Figure 2B** [↗](#)) where the INTS12 KO alone reactivates HIV, and INTS12 KO further improves reactivation with AZD5582 & I-BET151.

Reads were also mapped along the length of the HIV provirus (**Figure 3B** [↗](#)) using PMAi treated cells in this comparison as a positive control known to induce full length transcripts (Falcinelli et al., 2022 [↗](#)) (**Figure 3B** [↗](#), bottom row). We observe the same differences quantified in (**Figure 3A** [↗](#)) as well as similar pileup trends along the length of the provirus. Because RNAs lacking a polyA tail are degraded rapidly (Biziaev et al., 2024 [↗](#)) it is unclear whether those RNAs were successfully captured in our assay, and it is likely we are only looking at full length RNA detection. Nevertheless, the total RNA-seq results show that INTS12 KO increases HIV proviral activation at the transcriptional level.

We also investigated how INTS12 KO and AZD5582 & I-BET151 treatments alone and in combination affect transcription in the cell at a global level to assess the specificity to HIV compared to host genes. We first compared our AZD5582 & I-BET151 treatment condition to the DMSO treated AAVS1 KO cells and found that 80 genes were upregulated and 306 were downregulated, and that HIV was the most upregulated transcript with the highest fold-change (FC) and was highly expressed as indicated by counts per million (CPM) (**Figure 4A** [↗](#), left panel), similar to previous work (Falcinelli et al., 2022 [↗](#)). Surprisingly, given the more wide-spread reported role of Integrator in transcription, we find that INTS12 KO alone is even more specific to HIV transcripts than AZD5582 & I-BET151 treatment, where we find the same level of enrichment of HIV as the previous comparison with a FC of 8, but there are only 70 upregulated genes and only 3 downregulated genes (**Figure 4A** [↗](#), middle panel). This indicates that INTS12 is more important to HIV transcription than it is to any other transcriptional unit in J-Lat cells.

On the other hand, the transcriptional landscape of the combination of INTS12 KO cells treated with AZD5582 & I-BET151 compared to AAVS1 KO cells that were treated with DMSO (**Figure 4A** [↗](#), right panel) showed an even greater enrichment of the HIV transcripts at a FC of ~28 ($\text{Log}_2(\text{Foldchange})=4.8$). However, this gain of potency came with some loss of specificity as there was greater dysregulation of the host with 255 upregulated genes and 159 downregulated genes compared to the INTS12 knockout alone or the AZD5582 & I-BET151 treatment alone.

Among the host genes most prominently affected by INTS12 knockout with AZD5582 & I-BET151 are MAFA, MAFB, and ID2 (full list of genes and results in supplemental file S3, tabs 1-4). Nonetheless, INTS12 knockout with AZD5582 & I-BET151 was much more specific to HIV-1 than PMAi, which can robustly activate HIV but at the cost of affecting thousands of host transcripts (**Figure 4B** [↗](#)). Thus, we find that INTS12 knockout acts at the transcriptional level in activating HIV from latency and is more specific for the HIV LTR than AZD5582 & I-BET151 treatment alone. We also find that INTS12 knockout indeed improves potency of reactivation of AZD5582 & I-BET151 but at the cost of some specificity.

Chromatin localization reveals INTS12 may act directly on HIV transcription and INTS12 knockout paired with AZD5582 & I-BET151 overcomes an elongation block to HIV transcription

The effect of INTS12 on HIV-1 transcription could be direct (i.e. the Integrator complex directly affecting the steady-state levels of HIV-1 RNA transcription) or could be indirect by affecting the transcription of other gene products that subsequently act on the HIV-1 LTR. In order to partially distinguish these two hypotheses, we asked if INTS12 is present at the HIV-1 LTR using Cleavage Under Targets and Tagmentation (CUT&Tag) for profiling chromatin components (Janssens et al., 2021 [↗](#)) using an antibody to INTS12 (**Figure 5A** [↗](#)). Using this approach, we observed that INTS12 is indeed at the LTR of HIV-1 as the signal over the LTR is greater in the AAVS1 KO cells than in




Figure 3

INTS12 KO reactivates HIV alone and in combination with AZD5582 & I-BET151 at the level of steady-state viral transcripts.

(A) Total RNA-seq reads mapping to the HIV provirus were averaged for biological triplicates normalized to copies per million reads (CPM). One way ANOVA, Šídák's multiple comparisons tests, p -value = <0.05 = *, <0.01 = **, <0.001 = ***, <0.0001 = ****. Readcounts of the HIV-1 provirus in the AAVS1 KO treated with DMSO average about 30 CPM while readcounts of the HIV-1 provirus in the INTS12 KO treated with AZD5582 and IBET-151 average about 800 CPM **(B)** Pileup graphs corresponding to each of the conditions represent averaged reads from biological triplicates that have been normalized to CPM, and the peaks correspond in location to the integrated provirus with viral genes labeled below. The scale of the pileups is in the top left of each row. Note that PMAi has a different scale than the other samples. The 3' LTR is masked so that reads will only map to the 5' LTR. AZD = AZD5582, IBET = I-BET151, PMAi = PMA & Ionomycin. All chromosome locations and quantified regions can be found in the methods. Cells used in this figure have an INTS12 knockout score of 75%.




Figure 4

Specificity of INTS12 KO for reactivation of HIV on its own and in combination with AZD5582 & I-BET151.

Differentially expressed genes are graphed by Log₂ (Fold Change) on the y axis, denoting how upregulated (red) or downregulated (blue), a gene is, and the average counts per million (CPM) on the x axis, denoting the expression of each gene. The big red dot denotes the average of all reads mapping to the HIV provirus. The red number at the top of each graph corresponds to the number of significantly upregulated genes in a comparison and the blue number in the bottom corresponds to number of significantly downregulated genes in a comparison. Grey genes are not statistically significant and not up or downregulated. **(A)**, left panel shows the effect of AZD5582 & I-BET151 treatment alone compared to the DMSO control. **(A)**, middle panel shows the effect of the INTS12 KO on gene expression compared to the AAVS1 KO control. **(A)**, right panel shows the effect of both AZD5582 & I-BET151 treatment of INTS12 KO cells compared to the control DMSO treated AAVS1 KO cells. **(B)** Is graphed using a different scale than A and shows the effect of PMAi treatment compared to the DMSO control. Cells used in this figure have an INTS12 knockout score of 75%.

cells with the partial INTS12 knockout (**Figure 5A** [↗](#), left panel, compare top two rows with bottom two rows). We also saw this effect with a different INTS12 antibody (**Figure 5** [↗](#)—figure supplement 1). We found that that INTS12 localization extends past the LTR, matching what has been seen previously, where Integrator members localize to sites of pausing which are past the site of initiation (Elrod et al., 2019 [↗](#); Stadelmayer et al., 2014 [↗](#)). In the right panel of **Figure 5A** [↗](#) we quantify all reads in the region specified by the dotted grey lines in the left panel (**Figure 5A** [↗](#), right panel; exact coordinates are in the methods). These results indicate INTS12 binds to the HIV promoter suggesting that INTS12 represses HIV-1 activation from latency through a direct mechanism.

Given the Integrator complex's role in pausing and termination at promoters, we wanted to look at HIV-1 elongation by measuring RNAPII levels as well as the Ser2 and Ser5 phosphorylation levels of the C-terminal tail of RNAPII with CUT&Tag. We first used an antibody against total RNAPII, RPB3, and generated pileup graphs of reads corresponding to where RPB3 is bound across the HIV-1 provirus and downstream (**Figure 5B** [↗](#), left panel). The peaks in each row correspond to at least 3 to 5 technical replicates averaged together. We quantified all reads of RPB3 in three regions (**Figure 5B** [↗](#), right panel; exact coordinates in the methods). We see similar levels of RPB3 in region 1 for all four conditions. We defined region 2 as the remainder of the provirus excluding the LTR and the short 5' region of region 1. We found that there was a dramatic statistically significant increase in RPB3/RNAPII occupancy in the body of the provirus (region 2) only with both INTS12 KO and AZD5582 & I-BET151 together (**Figure 5B** [↗](#)). We did not see this increase in RNAPII when we examined the gene downstream of the integrated provirus (region 3). More RNAPII within HIV is suggestive of elongation, but to strengthen this claim we measured Ser2 phosphorylation of the C-terminal tail of RNAPII that is found on the elongation competent form of RNAPII. We observed evidence of elongation competent RNAPII for two conditions with LRAs: AAVS1 KO cells treated with AZD5582 & I-BET151 and our INTS12 KO cells treated with AZD5582 & I-BET151 (**Figure 5C** [↗](#)), as we saw a significant increase in reads in region 2 compared to the AAVS1 KO treated with DMSO control. When we tested RNAPII Ser5 phosphorylation, a marker not associated with elongation, we did not observe any statistically significant differences in any region for the same conditions tested in **Figure 5B** [↗](#) and **C** [↗](#) (**Figure 5** [↗](#)—figure supplement 2). Therefore, these data support the hypothesis that the combination of INTS12 with AZD5582 & I-BET151 specifically overcomes an elongation block that the INTS12 KO and AZD5582 & I-BET151 alone cannot overcome.

INTS12 knockout improves latency reversal *ex vivo* in T cells from virally suppressed people living with HIV (PLWH)

We next tested the role of INTS12 in HIV-1 latency reversal in an *ex vivo* system of CD4 T cells isolated from PBMCs of virally suppressed PLWH. CD4 T cells were electroporated with Cas9 complexed with either a non-targeting control guide (NTC), or a cocktail of 3 INTS12 guides and then treated with DMSO (vehicle) or AZD5582 & I-BET151 treatment for 24hrs (**Figure 6A** [↗](#) and **B** [↗](#)). We used a low reactivating dose of AZD5582 (100nM) & I-BET151 (500nM) for primary cell experiments (Falcinelli et al., 2022 [↗](#)). We tested six different donors with or without AZD5582 & I-BET151 treatment and measured cell-associated viral RNA expression by qPCR using primers in *gag* (**Figure 6A** [↗](#) and **B** [↗](#)). In **Figure 6A** [↗](#), when we treat donors with the vehicle control (DMSO), we find that INTS12 KO trends upwards for viral RNA expression in all six donors and this increase is statistically significant in four donors (**Figure 6A** [↗](#)). These same samples were treated with AZD5582 & I-BET151 (**Figure 6B** [↗](#)), and we found that although LRAs alone could activate viral RNA expression (compare samples in **Figure 6A** [↗](#) with 6B), the combination of AZD5582 & I-BET151 paired with the INTS12 KO shows an even further increase in HIV-1 reactivation that was statistically significant in four out of six donors (**Figure 6B** [↗](#)). For donor PH543 (upside down triangle), we found that there is an increase from the INTS12 KO itself (**Figure 6A** [↗](#), right panel), and robust activation from AZD5582 and I-BET151 treatment itself (**Figure 6B** [↗](#), right panel), however there was no further increase from INTS12 KO with AZD5582 & I-BET151 treatment.




Figure 5

INTS12 binds the HIV promoter and INTS12 KO paired with LRAs increases occupancy of elongation-competent RNAPII through the provirus.

CUT&Tag using antibodies to INTS12 (**A**), total RNAPII (RPB3) (**B**), or RNAPII Ser2 phosphorylation (Ser2p) (**C**) were used to generate pileup graphs that show where each are binding chromatin. The location of where reads are mapping is denoted below the tracks, and the scale are the numbers on the left of each row. Each row represents three to five technical replicates averaged together. The 3' LTR is masked so that reads will only map to the 5' LTR. (**A**, left panel) shows a zoom in of the HIV LTR and where INTS12 is binding. (**A**, right panel) quantifies total reads of INTS12 in the area denoted by the grey dashed lines in the left panel. (**B**, left panel) shows where RPB3 is binding across the HIV provirus and downstream. (**B**, right panel) quantifies total reads of RPB3 in the regions denoted by the grey dashed lines in the left panel, regions 1-3. (**C**, left panel) shows where RNAPII Ser2p is found across the HIV provirus and downstream. (**B**, right panel) quantifies total reads of RNAPII Ser2p in the regions denoted by the grey dashed lines in the left panel, regions 1-3. All chromosome locations and quantified regions can be found in the methods. Two-tailed independent samples t-test p-value = <0.05 = *, <0.01 = **, <0.001 = ***, <0.0001 = ****. Cells used in this figure have an INTS12 knockout score of 80%.

Degree of reactivation was correlated with reservoir size as donors PH504 (star symbol) and PH543 (upside down triangle) have the largest HIV reservoirs (supplemental file S4). This data shows that our screen was able to identify INTS12 as a barrier to HIV-1 reactivation in PLWH, as we find that there is reactivation from INTS12 knockout alone and improvement of AZD5582 & I-BET151 treatment with the addition of INTS12 knockout in a majority of virally suppressed PLWH tested *ex vivo*.

Because elongation of full-length HIV RNA has been a barrier to reactivation in PLWH previously, we not only wanted to look within the cells at *gag* RNA expression, but we sought to measure viral RNA in the supernatant by qPCR as a proxy for virus production. For this repeat assay, we chose three donors that had available materials (labelled in green in **Figure 6**). We used the same LRA concentrations we used in **Figure 6A** and **B**, but extended the time of treatment to 72 hrs, and measured viral RNA in the supernatant (**Figure 6C**). Importantly, we observed for all three donors that INTS12 KO was able to improve reactivation either on its own or in the presence of AZD5582 & I-BET151. Excitingly, donor 543 (**Figure 6C**, right panel) showed a robust increase from the pairing of INTS12 KO with AZD5582 & I-BET151 treatment when measuring *gag* RNA in the supernatant. The differences between **Figure 6C** and **Figure 6B** for donor 543 could be due to timing of the assay, or alternatively, that pairing INTS12 KO with AZD5582 & I-BET151 results in more efficient full-length viral RNA such that we do not see an increase within the cell with the addition of INTS12 KO (**Figure 6B**) as more RNA is in the supernatant (**Figure 6C**, difference between LRA with or without INTS12 KO). Nevertheless, we can conclude that the majority of these s are responsive to INTS12 KO with or without AZD5582 & I-BET151 treatment and that this reactivation leads to full length HIV that can be detected in the supernatant.

Role of additional members of the Integrator complex in HIV latency reversal

Previous studies have shown that Integrator members are important for HIV latency (Stadelmayer et al., 2014), and some have done so in the context of combination LRA treatment (Li et al., 2020). In our initial screen of epigenetic factors (**Figure 1**), only INTS12 was included in the CRISPR guide library of the fifteen-member Integrator complex. In order to more comprehensively interrogate the role of Integrator complex members in HIV latency, we remade a library of guides in the HIV-CRISPR vector where we included all Integrator members (with the exception of INTS15 that was not known at the time of library construction (Offley et al., 2023; Replogle et al., 2022)). The remainder of this library targets NF- κ B related factors (supplemental file S5). We took this new library (herein, Screen #2) and treated J-Lat 10.6 cells with 1nM AZD5582 & 2.5 μ M I-BET151 for 24hrs (**Figure 7**) and found INTS12 is again predicted to improve the AZD5582 & I-BET151 treatment as it falls above the average NTCs. Importantly, however, all members of the cleavage module: INTS11, INTS9, INTS4; all members of the phosphatase module: INTS5, INTS6, INTS8; and all members of the core: INTS1, INTS2, INTS7 score positively in our screen. Thus, we predict that a large majority of the Integrator complex, consisting of the cleavage module, phosphatase module, core, and INTS12, but not the SOSS complex or the enhancer/arm module, likely play a role in HIV latency reversal in the presence of LRAs.

Given that the Integrator complex acts on the late elongation stage in viral transcription, it is possible that it serves as a more general block to HIV reactivation and therefore, we would expect that INTS12 knockout could improve an even broader subset of LRAs than AZD5582 & I-BET151. We took our AAVS1 KO cells or INTS12 KO cells and reactivated with TNF- α , a canonical NF- κ B activator, or anti-CD3/anti-CD28 co-stimulation that activates T cells through the T cell receptor and observed that INTS12 KO is able to increase reactivation with both of these stimuli (**Figure 7B**, left panel). Additionally, we tested these same cells with SAHA, an HDAC inhibitor that falls within the chromatin modification LRA class, for 24 hrs and we observe greater reactivation in




Figure 6

INTS12 knockout in an *ex vivo* primary cell system shows reactivation from knockout alone and in combination with AZD5582 & I-BET151.

Number of gag copies/ug of RNA were measured from the cell (A-B) or the supernatant (C) for different donors, marked by different symbols, above. (A) INTS12KO (12KO) was compared to a non-targeting control (NTC). (B) AZD5582 & I-BET151 treated INTS12 KO (AB + 12KO) was compared to AZD5582 & I-BET151 treatment (AB). Unpaired t-test, p-value = <0.05 = *, = <0.01 = **, = <0.001 = ***, = <0.0001 = ****. The green coloration denotes samples that are in common between A-C. (C) gag in the supernatant was measured for three different donors. Two-way ANOVA p-value = <0.05 = *, = <0.01 = **, = <0.001 = ***, = <0.0001 = ****.

our 250 nM and 1000 nM conditions in our INTS12 KO cell than AAVS1 KO cells (**Figure 7B**, right panel). Therefore, INTS12 knockout was able to increase reactivation with all LRAs tested, which supports the idea that INTS12 serves as a general block to reactivation for HIV.

Discussion

We sought to improve HIV reactivation with a synergistic LRA combination AZD5582 & I-BET151 using an CRISPR screening approach. The ideal gene target would not only increase potency of this drug combination but maintain specificity to the virus and limit off-target effects. We used an epigenetic regulatory factor focused guide library in combination with AZD5582 & I-BET151 and identified INTS12. We validated that knockout of INTS12 results in increased latency reversal on its own but more in the presence of AZD5582 & I-BET151 treatment, as the screen predicted. We observed that INTS12 KO resulted in specific enrichment of HIV and minimal effects on host genes, and that INTS12 KO is more specific to HIV than AZD5582 & I-BET151 treatment alone. INTS12 KO paired with AZD5582 & I-BET151 treatment further increased potency of HIV reactivation, but some specificity was lost compared to AZD5582 & I-BET151 alone and INTS12 KO alone.

However, INTS12 KO paired with AZD5582 & I-BET151 remains more specific to HIV than PMA & Ionomycin combination treatment. With CUT&Tag, we observed that INTS12 is at the HIV promoter which supports that it is acting directly on HIV-1 transcription, and we see an increase in elongation-competent RNAPII in the gene body of HIV only with the combination of INTS12 KO and AZD5582 & I-BET151, supporting that an elongation block is specifically overcome with this combination. Additionally, we validated INTS12 in an *ex vivo* primary cell model of latency where we see reactivation from INTS12 KO in a majority of donors tested with or without AZD5582 & I-BET151 treatment, and that reactivation upon INTS12 KO leads to detection of viral RNA in the supernatant indicating that full length HIV is likely generated. Furthermore, we used the CRISPR-screen approach to predict which members of the Integrator complex could be targeted to improve the AZD5582 & I-BET151 combination and identified the cleavage module, phosphatase module, and core Integrator members, in addition to INTS12 as playing a role in HIV-1 latency. Lastly, we demonstrated that INTS12 knockout can improve reactivation of a diverse set of stimuli supporting that INTS12 serves as a general block to reactivation of HIV. This study highlights the promise of using the CRISPR-screening approach as a tool to identify blocks to HIV reactivation and improve LRA combinations, such as AZD5582 & I-BET151.

The role of Integrator complex in modulating HIV transcription

The Integrator complex is known to regulate and attenuate transcription at promoters that are bound by pausing factors NELF and DSIF (Skaar et al., 2015). HIV is known to be regulated by these pausing factors (Ping & Rana, 2001), and recently it has been shown that members of the Integrator are recruited to the HIV TAR loop and regulate processivity of HIV transcription (Stadlmayer et al., 2014). The Integrator contains 15 members that fall within different submodules that perform various functions (Welsh & Gardini, 2023), and of these modules some members of the cleavage, phosphatase, and core have been shown to reverse HIV latency upon knockout (Li et al., 2020; Stadlmayer et al., 2014). Knockout of INTS3 of the SOSS complex was also not found to reverse latency in a previous study (Stadlmayer et al., 2014). Furthermore, members of the core and phosphatase have been shown to improve an LRA combination of a BET inhibitor with a PKC agonist (Li et al., 2020). We have recapitulated these previous findings (**Figure 7**), but we have also predicted that all members of these modules can be targeted to improve the AZD5582 & I-BET151 treatment including the cleavage module for which this has not been explored in the context of LRAs.

One study explored the different effects on gene transcription upon targeting the cleavage module vs targeting the phosphatase module of the Integrator complex (Hu et al., 2023 [\[1\]](#)). Selectively targeting the cleavage module of Integrator has been shown to result in a specific induction of lowly expressed genes, since these genes are regulated by pausing factors and Integrator (Hu et al., 2023 [\[1\]](#)). Given that HIV is regulated by these same factors and poorly expressed during HIV latency, it may not be surprising that targeting this module has shown an increase in HIV transcription. Since the Integrator complex has been shown to modulate genes differently in the presence or absence of stress stimuli (Tatomer et al., 2019 [\[2\]](#); Yue et al., 2017 [\[3\]](#)) this may explain why targeting the Integrator complex in the presence of LRAs can improve reactivation. Moreover, Integrator is known to antagonize host PTEF-b function with its phosphatase module and enforce pausing at bound promoters. Therefore, targeting the phosphatase module can lead to more elongation at affected promoters. Given that HIV is sensitive to pausing and elongation, especially in cells from PLWH, and PTEF-b is considered to be one of the major rate-limiting steps to HIV reactivation, it is reasonable that removing a PTEF-b antagonist would help aid in HIV reactivation. Our results are also consistent with the hypothesis that transcription elongation with INTS12 KO cells treated with AZD5582 & I-BET151 may be more efficient than the LRAs alone, as the levels of Ser2 phosphorylation of the C-terminal tail of RNAPII are also significantly lower near the LTR, but increased distal to the LTR (Figure 5C [\[4\]](#), compare INTS12 KO treated with AZD5582 & I-BET151 to DMSO in region 1 and region 2), which may suggest RNAPII is efficiently leaving the promoter and traveling within the body of the provirus to affect full-length transcription. This full-length transcription is also consistent with increased virus release that we observe both in cell lines and in primary cells (Figure 2 [\[5\]](#) and Figure 6C [\[6\]](#)).

INTS12 as a target for small molecule drug development

While our data suggests many different members of the Integrator complex could be targeted to activate HIV-1 (Figure 7A [\[7\]](#)), we believe that INTS12 may be the better option to target over the rest of the complex. We find that INTS12 is located at the HIV-1 promoter (Figure 5A [\[4\]](#)) and knockout fairly specifically reactivates HIV compared to host genes (Figure 4A [\[8\]](#), middle panel) which supports that this complex acts directly on HIV-1 transcription rather than indirectly through the modulation of other genes. Therefore, targeting INTS12 may keep other activities of the Integrator complex partially intact. It is possible knocking out INTS12 may alter where those activities are exerted as this member is thought to toggle chromatin localization, or it is possible INTS12 may be performing a separate function entirely from the remainder of the Integrator complex. Other studies have also suggested that INTS12 knockdown does not grossly affect cell viability (Kheirallah et al., 2017 [\[9\]](#)), as opposed to other members of the Integrator complex (Rienzo & Casamassimi, 2016 [\[10\]](#)), although it has been shown that catalytic members have been able to be targeted for short periods of time without signs of catalytic activity disruption in cell lines (Elrod et al., 2019 [\[11\]](#)). With the caveats that the function of INTS12 in diverse T cell functions or other *in vivo* functions is not yet known and needs to be investigated in humans, we propose that toggling INTS12 with a small molecule drug may be even more successful with short term disruption in the shock-and-kill approach.

Ex vivo Primary Cell system

To our knowledge, our study is the first to report an analysis of an Integrator complex member in an *ex vivo* experiment in cells from virally suppressed PLWH. We observed that INTS12 knockout reactivates HIV transcription in a majority of donors on its own and especially in the presence of AZD5582 & I-BET151 (Figure 6 [\[12\]](#)). This was in people with differing reservoir sizes, cells that have different HIV integration sites, and people on ART treatment for varying lengths of time. We were also able to show that HIV RNA could be detected in the supernatant, which is an aspect critical to consider with regard to the kill side of the shock- and-kill approach and has proven to be one of the more difficult elements of the approach so far with many studies showing reactivation but variable virus production. This result highlights the power in the CRISPR-screening approach and

shows that even when cell line models are used, we can use LRA combinations and identify blocks to reactivation that can be used to improve reactivation in more clinically relevant cells from PLWH.

Synergy on multiple mechanisms

AZD5582 and I-BET151 are thought to synergize by acting to undo different blocks to latency reversal. AZD5582 working on the transcription initiation arm where non canonical NF- κ B is upregulated and I-BET151 on the transcription elongation arm where it is thought to impact available cellular PTEF-b that can work in conjunction with HIV Tat for HIV transcription (Jang et al., 2005 [\[3\]](#); Schroder et al., 2012 [\[3\]](#); Turner, 2024; Yang et al., 2005 [\[3\]](#)). When Integrator is bound to the HIV promoter it can attenuate HIV transcription through its cleavage and phosphatase modules, as evidenced by knockout of members of these modules. As such, Integrator works on the elongation stage of transcription, and in our work, we have evidence that knocking out INTS12 overcomes a block to elongation. We not only see virus in the supernatant upon INTS12 KO in cells from PLWH (**Figure 6C** [\[3\]](#)), but we also see that specifically with the combination of INTS12 KO and AZD5582 & I-BET151 there is an increase in elongation-competent RNAPII downstream of the HIV promoter and throughout the HIV provirus (**Figure 5B** [\[3\]](#) and **C** [\[3\]](#)). Therefore, our hypothesis is that targeting Integrator may allow for HIV transcription initiation events to not be aborted prematurely and allow for subsequent paused promoters to proceed to elongation from an unopposed PTEF-b. For this reason, removal of Integrator can lead to latency reversal on its own, but this also may explain why Integrator increases latency reversal with each LRA individually as well as improves the combination of INTS12 knockout with AZD5582 & I-BET151.

The Integrator complex itself is a fascinating target that needs to be considered for any cure approach involving transcription. Not only does it govern transcription regulation at the HIV promoter (**Figure 3** [\[3\]](#)), but it appears to do so in ways that may be contrary to the ways other genes are affected given its relative specificity for HIV transcripts (**Figure 4A** [\[3\]](#), middle panel), and has the ability to influence reactivation with diverse LRAs. While it has been reported that Integrator can function differently in the presence of stress stimuli (Tatome et al., 2019 [\[3\]](#); Yue et al., 2017 [\[3\]](#)) we did not observe differential expression of any Integrator members upon AZD5582 & I-BET151 treatment in J-Lat cells (supplemental file S3, tabs 1 and 5) though this does not mean that recruitment of the complex does not vary under stimulatory conditions. In **Figure 5** [\[3\]](#), we did not observe significantly different recruitment of INTS12 to the HIV LTR upon AZD5582 & I-BET151 treatment but did not look at recruitment of other Integrator members and how their recruitment may be impacted. It is possible the general stoichiometry of the various Integrator members is important for the function of the complex at various promoters, though this has not been explored. Understanding how the Integrator complex and its various modules are affected by different LRA stimuli may be crucial to optimizing the shock-and-kill strategy or even improving the reverse strategies of block-and-lock (Lyons et al., 2023 [\[3\]](#)) seeking to silence HIV more effectively at the HIV promoter. While, to our knowledge, small molecule drugs that target INTS12, or any member of the Integrator complex are not yet available, the development of such agents would be predicted to improve the efficacy of existing LRAs to achieve more effective viral reactivation as a step towards reservoir reduction.

Materials and Methods

Data Availability

All primary CUT&Tag sequencing data, RNA-seq data, and screen data can be found at GSE277306.

Ethics Statement

PBMC for this study were obtained from durably suppressed on ART people living with HIV under a University of North Carolina (UNC) institutional Review Board approved protocol (study number 08-1575). All Participants provided written consent.

Cell Culture and Maintenance

J-Lat 10.6 and J-Lat 5A8 cells were cultured with RPMI 1640 media (ThermoFisher, 11875093) supplemented with 10% Fetal Bovine Serum (FBS), Penicillin/Streptomycin, and 10 mM HEPES (ThermoFisher, 15630080). HEK293T and TZM-bl cells were cultured in DMEM (ThermoFisher, 11965092) supplemented with Penicillin/Streptomycin and 10% FBS. All cells were maintained at 37°C with 5% CO₂.

CRISPR screen: Human Epigenetic (HuEpi) Library

The HuEpi screen was performed as described in (Hsieh et al., 2023 [DOI](#)). Previously, J-Lat 10.6 and J-Lat 5A8 cells were prepared for the HIV-CRISPR latency screen by knocking out Zinc Antiviral Protein (ZAP), and the Human Epigenome Guide Library (HuEpi) was cloned into HIV-CRISPR vectors. Specific details for this paper below.

HuEpi screen: Lentivirus production

Lentivirus was made by adding 667 ng of previously prepped HuEpi HIV-CRISPR vectors (Hsieh et al., 2023 [DOI](#)), 500 ng psPAX2 (GagPol), and 333 ng MD2.g (VSVG) per well in 200 µl of serum-free DMEM and completed with 4.5 µl of TransIT-LT1 reagent (Mirus Bio LLC, MIR 2304). 20 × 6 well cell culture plates of 293Ts were used at a confluency of 40-60%. Media was replaced 24 hrs after transfection (and reduced to 1.5 ml/well) and the VSV-G pseudotyped lentivirus was harvested 48 hrs after that and filtered through a 0.22 µm filter (Thermo Scientific; 720–1320). Virus supernatant was combined (by cell type) and concentrated by ultracentrifugation. For ultracentrifugation, about 30 mL of supernatant was aliquoted into each polypropylene tube (Beckman Coulter; 326823) and sterile-filtered 20% sucrose (20% sucrose, 1 mM EDTA, 20 mM HEPES, 100 mM NaCl, distilled water) was added slowly underneath to form a sucrose cushion. Tubes were then placed in a pre-chilled swinging buckets SW 28 rotor at 23,000 rpm for 1 hour at 4°C in a Beckman Coulter Optima L-90K Ultra-centrifuge. Supernatants were decanted, allowed to dry briefly, and pellets were resuspended overnight in 600 µL RPMI at 4°C (can do several hours). Concentrated lentivirus was then stored at -80°C in single use small aliquots (~150 µL) and two 50µl aliquots were stored at -80°C for titration.

HuEpi screen: HuEpi HIV-CRISPR cell generation

Virus was titrated on TZM-bl cells (NIH AIDS Reagent Program; ARP-8129) in a colony-forming assay to calculate for a <1 multiplicity of infection (MOI) (0.54 was used in the HuEpi screens). Number of cells to transduce were calculated to be >500x (5029 HuEpi guides x 500 = 2.51e6 + error = 3e6 cells) so 3e6 J-Lat cells (ZAP KO) were transduced per replicate. Cells were transduced with DEAE-Dextran (20 µg/mL final concentration, Sigma-Aldrich; D9885)) and spinoculated for 30 minutes at 1100 xg and incubated overnight. After 24 hrs, supernatant was replaced with fresh media containing 0.4 µg/mL of puromycin (Sigma) and cells were selected for 10-14 days (cells were grown for 21 days in this experiment to acquire enough for the desired screen coverage and all experimental conditions).

LRA resuspension

AZD5582 (MedChemExpress, HY-12600), I-BET151 (SelleckChem, S2780) TNF-α (Peprotech, 300-01A), SAHA (Selleckchem, S1047), and Tazemetostat (Selleckchem, S7128) were resuspended in DMSO to make 10 mM stocks stored at -80 °C. Stocks were then diluted down to single-use working

concentrations for experiments with RPMI.

T-cell activation

Anti-Human CD3 antibody (Tonbo Biosciences, 40-0038-U500), Anti-Human CD28 antibody (Tonbo Biosciences, 40-0289-U500).

HuEpi screen: LRA treatments

For the LRA treatments in the screen, we use a coverage of 5000x in case reactivation events are rare and we also account for viability. We calculated 25e6 cells were needed per replicate + error = 26e6 cells. We accounted for AZD5582's viability and calculated 35e6 cells/replicate for each condition. AZD5582 and I-BET151 were resuspended in DMSO to 1 mM stocks stored at -80°C. All other dilutions were performed in RPMI and used immediately. For the screen, 35e6 cells/replicate were grown at 5e5 cells/ml in a flask and treated with 10 nM AZD5582, 100 nM I-BET151, 10 nM AZD5582 & 100 nM I-BET151, or DMSO. Cells and supernatants were collected after 48 hrs of stimulation. Cells were spun down at 1500 x g for 3 min, supernatants were transferred to a new 50 ml conical, filtered through a 0.22 µm filter (Millipore Sigma, SE1M179M6), and stored at 4°C (can store over-night) for virus concentration. Cells were washed once with DPBS (Gibco; 14190144) and resuspended in 1 mL DPBS to store aliquots of 5e6 cells (approximately calculated, not counted) at -80°C. Finish concentrating virus by following steps detailed in lentivirus production (above) but resuspend the pellet in 150 µL at the end. Freeze viral supernatant at -80°C.

HuEpi screen: sample processing and prepping for sequencing

Genomic DNA from cell pellets were extracted with the QIAamp DNA Blood Midi Kit (Qiagen; 51183) and eluted in distilled water. vRNA from viral supernatant was extracted with the QIAamp Viral RNA Mini Kit (Qiagen, 52904). PCR 1: sgRNA sequences are in the gDNA and vRNA samples, they are amplified by PCR (Agilent; 600677) and RT-PCR (Invitrogen; 18064014), respectively, using HIV-CRISPR specific primers. PCR 2: adds barcodes and prepares the libraries for Illumina sequencing (examples of barcodes in (Hsieh et al., 2023 [4](#))). Each amplicon was cleaned up using double-sided bead clean-up (Beckman Coulter; A63880), quantified with a Qubit dsDNA HS Assay Kit (Invitrogen; Q32854), and pooled to 10 nM for each library. Library pools are sequenced on a single lane of an Illumina HiSeq 2500 in Rapid Run mode (Fred Hutch Genomics and Bioinformatics shared resource).

HuEpi screen: screen analysis

Analysis was performed as described in (Hsieh et al., 2023 [4](#)). Briefly, sequencing reads were demultiplexed and assigned to samples, trimmed, and aligned to the HuEpi library with Bowtie. Guide enrichment or depletion was determined with the MAGeCK statistical package.

Screen #2 containing all Integrator complex members

This screen was performed the same as the HuEpi screen was described above, with the following changes. The library contains 517 genes (6 guides/gene) + 163 NTCs = 3265 guides total. 1 nM AZD5582 & 2.5 µM I-BET151 was used for LRA treatment at 24 hrs. Coverage during transduction was 500x, the coverage during LRA treatments was 3600x. 50 bp sequencing was performed on the MiSeq V3 platform by the Fred Hutchinson Cancer Research Center Genomics Shared Resources.

CRISPR KOs/electroporations

J-Lat cells (in [Figure 2A](#) [4](#), [Figure 3](#) [4](#), and [Figure 4](#) [4](#)) were knocked out for INTS12 or AAVS1 with single guides cloned in the HIV-CRISPR. Transduced cells were selected with 0.4 µg/mL puromycin selection for 10–14 days to generate CRISPR/Cas9-edited knockout pools. J-Lat cells (in [Figure 2B](#) [4](#) and [C](#) [4](#)) were knocked out for INTS12 using a cocktail of three guides from IDT (Predesigned Alt-R™ CRISPR-Cas9 guide RNA) or AAVS1 using a cocktail of three guides from

Synthego (ordered individually as gene knockout kit v2 and then pooled together) and Cas9 from IDT (Alt-R S.p. Cas9 Nuclease V3). Cells were electroporated using the SE Cell Line 4D-Nucleofector™ X Kit L from Lonza using the CL-120 pulse code and edited for at least 3 days before use. All guides used are located in supplemental file S2.

Vector for complementation

For the complementation experiment (**Figure 2B** [↗](#) and **C** [↗](#)), after cells were electroporated and knocked out with the cocktails of 3 guides detailed above, half of the cells were transduced with a vector containing INTS12 generated on VectorBuilder (pLV[Exp]-Puro-EF1a>hINTS12[NM_020395.4]) and selected with 0.4 µg /ml puromycin for 10 days before LRA treatments. Cells were double checked for knock by ICE analysis and knock out scores only dropped by ~5% during this selection period.

ICE analysis

PCR products of a region containing the edited site in INTS12 knockout cells and not edited site in AAVS1 knockout cells were compared using the Synthego ICE analysis software to generate a knockout score. All primers can be found in supplemental file S2.

LRA treatments

AAVS1 KO and INTS12 KO cells were seeded at a density of 5e5 cells/ml in 96 well plates with 200 µl/well or in flasks. LRA treatments were performed in triplicate. Cells were seeded and then the calculated amount of LRA was added on top with mixing and cells were incubated. All J-Lat experiments used 10 nM AZD5582 & 100 nM I-BET151 for 48 hrs except Screen 2 (**Figure 7** [↗](#)) used 1nM AZD5582 & 2.5 µM I-BET151 for 24 hrs. Primary cell experiments used 100 nM AZD5582 and 500 nM I-BET151 for 24 hrs for qPCR and then treatment was extended to 72 hrs for viral RNA detection in the supernatant. Cells were treated with 10 ng/ml TNF-α for 20hrs and SAHA for a concentration between 1000nM to 100nM for 24 hrs.

T-cell activation

96 well plate wells were coated with 0.25µl of anti-CD3 antibody in 50µl PBS overnight at 4 °C in a parafilm plate overnight. Wells were aspirated and 200µl of cells at a density of 5e5 cells/ml were added to the coated well. Anti-CD28 antibody was added to be a concentration of 2mg/ml to the final well.

This stimulation went on for 20hrs before RT assay measurement.

Virus measurement: RT assay

LRA treated cells were spun at 1500 x g for 3 minutes and 50 µl of supernatant was transferred to 96 well plates. Plates were either processed immediately or were frozen at -80°C for future processing. For the RT assay, 5 µl of supe for each condition was mixed with lysis buffer and then diluted in H₂O before use as template for qPCR. The detailed protocol can be found here ([Vermeire et al., 2012](#) [↗](#)).

RNA-seq run/analysis

Three biological triplicates were generated in J-Lat 10.6 cells for AAVS1 KO and INTS12 KO cells by knocking out three separate sets of cells and then cells were treated with LRAs. We included AAVS1 treated with DMSO, AAVS1 treated with AZD5582 & I-BET151, INTS12 KO treated with DMSO, and INTS12 KO treated with AZD5582 & I-BET151. Treated samples were spun down at 1.45e6 cells/tube (I used 2 tubes/sample), supernatant was aspirated, and cells were lysed with 700 µl of QIAzol (Qiagen, 1023537). Samples were spun through a QIAshredder (Qiagen, 79654) and then frozen at -80°C. Cells were processed with a miRNeasy kit (Qiagen, 217004), DNase treated

with RNase-Free DNase Set (Qiagen, 79254), and then reprocessed through the RNeasy Mini Kit (Qiagen, 74104) with the EtOH wash modified to 700 μ L for small RNAs. Combine tubes for each sample. RNA quality was checked by TapeStation (all samples had a RIN of 10), and 10 μ L of RNA at 50 ng/ μ L was sent for RNA-seq to the Fred Hutchinson Cancer Center Genomics Shared Resources where rRNA was removed to select for the rest of the total RNA with the Illumina Stranded Total RNA Prep, Ligation with Ribo-Zero Plus kit (20040525) followed by indexing with IDT for Illumina RNA UD Indexes Set A Ligation (20040553). Samples were run using paired-end 2 $\times$ 50bp sequencing on the NovaSeq S1 by the Fred Hutchinson Cancer Center Genomics Shared Resources.

RNA-seq: Data Analysis

Fastq files were aligned to the custom genome assembly prepared by (Hsieh et al., 2023 [DOI](#)) in which chr9:136468439–136468594 of hg38 is replaced with the integrated HIV-1 sequence from MN989412.1 (Chung et al., 2020 [DOI](#)), and the second 634 bp copy of the LTR is masked by ‘N’s. GENCODE annotation v38 and HIV gene annotation were combined and genome coordinates were modified accordingly. STAR v2.7.7a (<https://pub-med.ncbi.nlm.nih.gov/23104886/> [DOI](#)) with 2-pass mapping was used to align paired-end reads to the custom reference. FastQC 0.11.9 (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/> [DOI](#)), RNA-SeQC 2.3.4 (<https://pubmed.ncbi.nlm.nih.gov/22539670/> [DOI](#)), RSeQC 4.0.0 (<https://pub-med.ncbi.nlm.nih.gov/22743226/> [DOI](#)) were used to check various QC metrics including insert fragment size, read quality, read duplication rates, rRNA rates, gene body coverage and read distribution in different genomic regions. featureCounts (<https://doi.org/10.1093/bioinformatics/btt656> [DOI](#)) in Subread 2.0.0 was used to quantify gene-level read counts in second-stranded fashion. Bioconductor package edgeR 3.36.0 (<https://academic.oup.com/bioinformatics/article/26/1/139/182458> [DOI](#)) was used to detect differential gene expression between sample groups. Genes with low expression were excluded using edgeR function filterByExpr with min.count = 10 and min.total.count = 15. The filtered expression matrix was normalized by TMM method (<https://doi.org/10.1186/gb-2010-11-3-r25> [DOI](#)) and subject to significance testing using quasi-likelihood pipeline implemented in edgeR. A gene was deemed differentially expressed if absolute log2 fold change was above 1 (i.e. fold change > 2 in either direction) and Benjamini-Hochberg adjusted p-values was less than 0.05.

CUT&Tag: sample preparation

Nuclei were prepared from J-Lat 10.6 cells. Samples included AAVS1 treated with DMSO, AAVS1 treated with AZD5582 & I-BET151, INTS12 KO treated with DMSO, and INTS12 KO treated with AZD5582 & I-BET151. Treated cells were pelleted in 1.5 mL microfuge tubes (10e6 cells/sample) spun at 300 $\times$ g for 5 min, and then resuspended in 1 mL of ice cold NE1 Buffer (20 mM HEPES-KOH pH 7.9, 10 mM KCl, 0.5 mM Spermidine, 0.1% TritonX-100, 20% Glycerol, with Roche complete EDTA-free protease inhibitor tablet), and then incubated on ice for 10 min. Nuclei were centrifuged at 4°C at 1,300 $\times$ g for 4 min and then resuspended in 1 mL of Wash Buffer (20 mM HEPES pH7.5, 150 mM NaCl, 0.5 mM spermidine, supplemented with Roche complete EDTA-free protease inhibitor tablet). Nuclei were counted (10 μ L was used) and diluted to a concentration of 1e6 nuclei/900 μ L of wash buffer and aliquoted into cryovials with 100 μ L of DMSO, which were quickly placed inside a Mr. Frosty Isopropanol chamber for slow freezing at -80°C. Nuclei were then stored at -80°C until use. For automated CUT&Tag processing, nuclei were thawed at room temperature, washed in wash buffer, and bound to concanvalin-A (ConA) paramagnetic beads (Bangs Laboratories; BP531) for magnetic separation as described on the protocols.io website (<https://doi.org/10.17504/protocols.io.bgztjx6n> [DOI](#)). Samples were then suspended in antibody binding buffer and split for overnight incubation with antibodies specific to INTS12 (Thermo Fisher, 16455-1-AP) (**Figure 5A** [DOI](#)) or INTS12 (Abxexa, abx234360) (**Figure 5** [DOI](#), figure supplement 1) or RPB3 (Thermo Fisher, A303-771A), RNA-Pol2-S5p (Cell Signaling; 13523), RNA-Pol2-S2p (Cell Signaling; 13499), and IgG control (Abcam; 172730). Sample processing was performed in a 96 well plate using 25K Con-A bound nuclei per reaction on a Beckman Coulter Biomek liquid handling robot according to the AutoCUT&Tag protocol available from the protocols.io website (<https://doi.org/10.17504/protocols.io.bgztjx6n> [DOI](#)).

[.org/10.17504/protocols.io.bgztjx6n](https://doi.org/10.17504/protocols.io.bgztjx6n)) and described previously (Janssens et al., 2022) (Fred Hutch Genomics shared resource). Samples were run on the NextSeq P2 using paired-end 2 × 50 bp sequencing by the Fred Hutchinson Cancer Research Center Genomics Shared Resources.

CUT&Tag: Data Analysis

The same custom genome assembly as RNA-seq was used for CUT&Tag. Bowtie2 version 2.4.2 was used for alignments with the following parameters: `—very-sensitive-local—soft-clipped-unmapped-tlen—dovetail—no-mixed—no-discordant -q—phred33 -I 10 -X 1000`. For each target protein and each condition, 3-5 technical replicates were profiled. We removed duplicate reads from each replicate, and the combined reads for all replicates were pooled and used to generate the coverage-normalized bigwig files shown as genome-browser tracks. The number of unique reads for each replicate were quantified over the intervals indicated by the dotted grey lines in **Figure 5**, and we compared the read counts over the indicated intervals in the AAVS1KO AZD&IBET, INTS12KO DMSO and INTS12KO AZD&IBET conditions to the AAVS1KO DMSO control samples using a two-tailed independent samples t-test.

CUT&Tag: Chromosome Locations

Figure 3B: chr9 136,468,583 – 136,478,093; **Figure 5A**, right panel quantification: chr9 136,468,583 – 136,469,694; **Figure 5B-C**, right panel, region 1 quantification: chr9 136,468,583 – 136,469,694, **Figure 5B-C**, right panel, region 2 quantification: chr9 136,469,695 – 136,478,093, **Figure 5B-C**, right panel, region 3 quantification: 136,478,783 – 136,487,890

Primary cells: Isolation

CD4 T cells were isolated from PBMC obtained from ART suppressed PLWH and cultured in RPMI media supplemented with 10% FBS, Penicillin/Streptomycin, 10 mM HEPES, and 10 units per mL of IL-2. All cells from PLWH were obtained from the UNC clinical HIV cohort (Study number: 08-1575)

Primary cells: knockout and LRA treatment

HIV infected CD4 cells from PLWH *in vivo* were electroporated using the P2 Primary Cell 96-well Nucleofector® Kit, (V4SP-2096, Lonza, Cologne, Germany), according to the manufacture's protocol with slight modification (Ashokkumar et al., 2024): briefly, 2-3 × 10⁶ cells were washed twice with phosphate-buffered saline by centrifuging at 90g for 5 min and resuspended in nucleofection buffer P2. The resuspended cells together with RNP complexes were immediately transferred into the cuvette of the P2 Primary Cell Nucleofector Kit (Lonza; V4SP-2096) and electroporated using the program code, EH-100 on the Lonza 4D-Nucleofector. Electroporated cells were resuspended with 200μL of prewarmed supplemented RPMI media with IL-2 (10U/mL) and IL-7 (4ng/mL) and expanded in a 37°C incubator. Three days post nucleofection, cells were treated with combination of AZD5582 (100nM) and I-BET151 (500nM) or DMSO and the expression of cell-associated (24hr) and cell-free (72hr) gag was quantified by RT-qPCR. The cells were maintained at 1 × 10⁶ cells/mL with fresh media supplemented with IL-2 and IL-7 every 2-3 days. Pre-designed crRNA with higher off-target score targeting human gene, INTS12 (CTTTTGAGATGGACGG-TAAC, CACAATACCACACCAGCGA, and ACCAATGGATCTTTGACAGC), and/or scrambled guides (non-target control, NT) were obtained from IDT as controls. Annealing of crRNA and tracrRNA, preparation of CRISPR/Cas9 ribonucleoprotein complexes (RNPs). Three sgRNA targeting different regions of the target were multiplexed for more efficient target knockout.

Primary cell: RT-qPCR

Quantification of relative gene expression using quantitative-PCR One-step RT-qPCR HIV Gag RNA gene expression quantifications were performed as previously described [2] Briefly, RNA from independent donors were extracted using the RNeasy plus kit and QIAamp Viral RNA Mini Kit (Qiagen) for cell-associated and cell-free virus as per the manufacturer's instructions, respectively.

1 µg of nanodrop quantified RNA from Non-target (NT) or INTS12 gRNA nucleofected cells were reverse transcribed and amplified using Fastvirus (Thermo, Waltham, MA) and primer sets for HIV Gag RNA (GAG-F: ATCAAGCAGCCATGCAAATGTT, GAG-R: CTGAAGGGTACTAGTAG-TTCCTGCTATGTC, GAGProbe: FAM/ZEN-ACCATCAATGAGGAAGCTGCAGAATGGGA-IBFQ). Reactions were performed in 96-well plates using the Quant Studio 3 Real-Time PCR system (Applied Biosystems, Foster City, CA) real time thermocycler with a cycling parameters of 5 min reverse transcription step at 50°C, 95°C for 20 sec for Taq activation, followed by 40 cycles of 95°C (3 sec.), and 60°C (30 sec.). All qPCR reactions were performed in triplicate. Normalized relative expression levels were calculated using the Prism software version 10.1.1 (Graphpad).

Acknowledgements

We thank Steve Hahn and Toshi Tsukiyama for helpful discussions, Trine Ready for technical support, Jessie Kulsuptrakul for help with cell maintenance, Feinan Wu and Matthew Fitzgibbon for RNA-seq and CUT&Tag bioinformatics support, Alyssa Dawson and Alex Zevin for aid in RNA-seq set-up and sequencing, Merari Santana-Carbajal and Philip Corrin for aid in CUT&Tag set-up and sequencing, Harini Srinivasan for aid in constructing the library for Screen #2, Pritha Chanana for aid in analyzing Screen #2, Cindy Gay, Susan Pedersen, Caroline Baker, Taylor Whitaker and the staff of the UNC Blood Bank and UNC CTRC for clinical support, as well as all members of the Emerman lab and the CARE Collaboratory for helpful suggestions and discussions. We thank Warner Greene at Gladstone Institute of Virology and Immunology and University of California, San Francisco, San Francisco, CA, USA for sharing the J-Lat 5A8 cells. We thank the HIV seropositive participants for their altruism. This work was supported by DP1 DA051110 (ME), CARE 1UM1-A1-164567 (ME, NMA, EPB), NIAID R01 AI143381 (EPB), NIDA R61 DA047023 (EPB), R01 AI143381 (EPB), 1R56AI170226 (NMA) and RRID:SCR_022606; additionally, of the Fred Hutch/University of Washington/Seattle Children's Cancer Consortium (P30 CA015704). DHJ was supported by a Hartwell Foundation Postdoctoral Fellowship. EH was supported by the University of Washington (UW) Viral Pathogenesis training grant NIH T32 AI 083203. This paper was type-set with the bioRxiv word template by @Chrelli: www.github.com/chrelli/bioRxiv-word-template 

Additional information

Author Contributions

Conceptualization: CNG,EH,ME

Methodology: CNG, MA, DHJ, JK, BA, EM, TLH

Investigation: CNG, MA, DHJ, JK, BA, EM, TLH, NMA, EPB, ME

Visualization: CNG, TLH, MA

Funding acquisition: NMA, EPB, ME

Project administration: NMA, EPB, ME

Supervision: NMA, EPB, ME

Writing – original draft: CNG, MA, EPB, ME

Writing – review & editing: CNG, MA, DHJ, TLH, EH, NMA, EPB, ME

Additional files

Supplemental Figures [🔗](#)

Supplemental File S1 [🔗](#)

Supplemental File S2 [🔗](#)

Supplemental File S3 [🔗](#)

Supplemental File S4 [🔗](#)

Supplemental File S5 [🔗](#)

References

- Ait-Ammar A., Kula A., Darcis G., Verdikt R., De Wit S., Gautier V., Mallon P. W. G., Marcello A., Rohr O., Van Lint C. (2019) **Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs** *Front Microbiol* **10**:3060 <https://doi.org/10.3389/fmicb.2019.03060>
- Archin N. M., Liberty A. L., Kashuba A. D., Choudhary S. K., Kuruc J. D., Crooks A. M., Parker D. C., Anderson E. M., Kearney M. F., Strain M. C., Richman D. D., Hudgens M. G., Bosch R. J., Coffin J. M., Eron J. J., Hazuda D. J., Margolis D. M. (2012) **Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy** *Nature* **487**:482–485 <https://doi.org/10.1038/nature11286>
- Ashokkumar M., Mei W., Peterson J. J., Harigaya Y., Murdoch D. M., Margolis D. M., Kornfein C., Oesterling A., Guo Z., Rudin C. D., Jiang Y., Browne E. P. (2024) **Integrated Single-cell Multiomic Analysis of HIV Latency Reversal Reveals Novel Regulators of Viral Reactivation** *Genomics Proteomics Bioinformatics* **22** <https://doi.org/10.1093/gpbjnl/qzae003>
- Biziaev N., Shuvalov A., Salman A., Egorova T., Shuvalova E., Alkalaeva E. (2024) **The impact of mRNA poly(A) tail length on eukaryotic translation stages** *Nucleic Acids Res* **52**:7792–7808 <https://doi.org/10.1093/nar/gkae510>
- Chan J. K., Bhattacharyya D., Lassen K. G., Ruelas D., Greene W. C. (2013) **Calcium/calcineurin synergizes with prostratin to promote NF-kappaB dependent activation of latent HIV** *PLoS One* **8**:e77749 <https://doi.org/10.1371/journal.pone.0077749>
- Chun T. W., Fauci A. S. (1999) **Latent reservoirs of HIV: obstacles to the eradication of virus** *Proc Natl Acad Sci U S A* **96**:10958–10961 <https://doi.org/10.1073/pnas.96.20.10958>
- Chung C. H., Mele A. R., Allen A. G., Costello R., Dampier W., Nonnemacher M. R., Wigdahl B. (2020) **Integrated Human Immunodeficiency Virus Type 1 Sequence in J-Lat 10.6** *Microbiol Resour Announc* **9** <https://doi.org/10.1128/MRA.00179-20>
- Cohn L. B., Chomont N., Deeks S. G. (2020) **The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies** *Cell Host Microbe* **27**:519–530 <https://doi.org/10.1016/j.chom.2020.03.014>
- Dai W., Wu F., McMyn N., Song B., Walker-Sperling V. E., Varriale J., Zhang H., Barouch D. H., Siliciano J. D., Li W., Siliciano R. F. (2022) **Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir** *Sci Transl Med* **14**:eab3351 <https://doi.org/10.1126/scitranslmed.ab3351>
- Davey R. T., Bhat N., Yoder C., Chun T. W., Metcalf J. A., Dewar R., Natarajan V., Lempicki R. A., Adelsberger J. W., Miller K. D., Kovacs J. A., Polis M. A., Walker R. E., Falloon J., Masur H., Gee D., Baseler M., Dimitrov D. S., Fauci A. S., Lane H. C. (1999) **HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression** *Proc Natl Acad Sci U S A* **96**:15109–15114 <https://doi.org/10.1073/pnas.96.26.15109>

- Debrabander Q., Hensley K. S., Psomas C. K., Bramer W., Mahmoudi T., van Welzen B. J., Verbon A., Rokx C. (2023) **The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review** *J Virus Erad* **9**:100342 <https://doi.org/10.1016/j.jve.2023.100342>
- Duggan N. N., Dragic T., Chanda S. K., Pache L. (2023) **Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a Cure** *Viruses* **15** <https://doi.org/10.3390/v15122435>
- Elrod N. D., Henriques T., Huang K. L., Tatomer D. C., Wilusz J. E., Wagner E. J., Adelman K. (2019) **The Integrator Complex Attenuates Promoter-Proximal Transcription at Protein-Coding Genes** *Mol Cell* **76**:738–752 <https://doi.org/10.1016/j.molcel.2019.10.034>
- Falcinelli S. D., Peterson J. J., Turner A. W., Irlbeck D., Read J., Raines S. L., James K. S., Sutton C., Sanchez A., Emery A., Sampey G., Ferris R., Allard B., Ghofrani S., Kirchherr J. L., Baker C., Kuruc J. D., Gay C. L., James L. I., ..., Margolis D. M. (2022) **Combined noncanonical NF-kappaB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo** *J Clin Invest* **132** <https://doi.org/10.1172/JCI157281>
- Fianu I., Chen Y., Dienemann C., Dybkov O., Linden A., Urlaub H., Cramer P. (2021) **Structural basis of Integrator-mediated transcription regulation** *Science* **374**:883–887 <https://doi.org/10.1126/science.abk0154>
- Hennessy E. J., Adam A., Aquila B. M., Castriotta L. M., Cook D., Hattersley M., Hird A. W., Huntington C., Kamhi V. M., Laing N. M., Li D., MacIntyre T., Omer C. A., Oza V., Patterson T., Repik G., Rooney M. T., Saeh J. C., Sha L., ..., Whitston D. (2013) **Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582)** *J Med Chem* **56**:9897–9919 <https://doi.org/10.1021/jm401075x>
- Ho Y. C., Shan L., Hosmane N. N., Wang J., Laskey S. B., Rosenbloom D. I., Lai J., Blankson J. N., Siliciano J. D., Siliciano R. F. (2013) **Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure** *Cell* **155**:540–551 <https://doi.org/10.1016/j.cell.2013.09.020>
- Hsieh E., Janssens D. H., Paddison P. J., Browne E. P., Henikoff S., OhAinle M., Emerman M. (2023) **A modular CRISPR screen identifies individual and combination pathways contributing to HIV-1 latency** *PLoS Pathog* **19**:e1011101 <https://doi.org/10.1371/journal.ppat.1011101>
- Hu S., Peng L., Song A., Ji Y. X., Cheng J., Wang M., Chen F. X. (2023) **INTAC endonuclease and phosphatase modules differentially regulate transcription by RNA polymerase II** *Mol Cell* **83**:1588–1604 <https://doi.org/10.1016/j.molcel.2023.03.022>
- Jang M. K., Mochizuki K., Zhou M., Jeong H. S., Brady J. N., Ozato K. (2005) **The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription** *Mol Cell* **19**:523–534 <https://doi.org/10.1016/j.molcel.2005.06.027>
- Janssens D. H., Meers M. P., Wu S. J., Babaeva E., Meshinchi S., Sarthy J. F., Ahmad K., Henikoff S. (2021) **Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia** *Nat Genet* **53**:1586–1596 <https://doi.org/10.1038/s41588-021-00941-9>
- Janssens D. H., Otto D. J., Meers M. P., Setty M., Ahmad K., Henikoff S. (2022) **CUT&Tag2for1: a modified method for simultaneous profiling of the accessible and silenced regulome in**

single cells *Genome Biol* **23**:81 <https://doi.org/10.1186/s13059-022-02642-w>

Jordan A., Bisgrove D., Verdin E. (2003) **HIV reproducibly establishes a latent infection after acute infection of T cells in vitro** *EMBO J* **22**:1868–1877 <https://doi.org/10.1093/emboj/cdg188>

Kheirallah A. K., de Moor C. H., Faiz A., Sayers I., Hall I. P. (2017) **Lung function associated gene Integrator Complex subunit 12 regulates protein synthesis pathways** *BMC Genomics* **18**:248 <https://doi.org/10.1186/s12864-017-3628-3>

Laird G. M., Bullen C. K., Rosenbloom D. I., Martin A. R., Hill A. L., Durand C. M., Siliciano J. D., Siliciano R. F. (2015) **Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations** *J Clin Invest* **125**:1901–1912 <https://doi.org/10.1172/JCI80142>

Li W., Xu H., Xiao T., Cong L., Love M. I., Zhang F., Irizarry R. A., Liu J. S., Brown M., Liu X. S. (2014) **MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens** *Genome Biol* **15**:554 <https://doi.org/10.1186/s13059-014-0554-4>

Li Z., Hajian C., Greene W. C. (2020) **Identification of unrecognized host factors promoting HIV-1 latency** *PLoS Pathog* **16**:e1009055 <https://doi.org/10.1371/journal.ppat.1009055>

Lykke-Andersen S., Zumer K., Molska E. S., Rouviere J. O., Wu G., Demel C., Schwalb B., Schmid M., Cramer P., Jensen T. H. (2021) **Integrator is a genome-wide attenuator of non-productive transcription** *Mol Cell* **81**:514–529 <https://doi.org/10.1016/j.molcel.2020.12.014>

Lyons D. E., Kumar P., Roan N. R., Defechereux P. A., Feschotte C., Lange U. C., Murthy N., Sameshima P., Verdin E., Ake J. A., Parsons M. S., Nath A., Gianella S., Smith D. M., Kallas E. G., Villa T. J., Strange R., Mwesigwa B., O'Brien R. L., ..., Ott M. (2023) **HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing** *Viruses* **15** <https://doi.org/10.3390/v15112171>

Maina E. K., Adan A. A., Mureithi H., Muriuki J., Lwembe R. M. (2021) **A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure** *Curr HIV Res* **19**:14–26 <https://doi.org/10.2174/1570162X18999200819172009>

Mbonye U., Karn J. (2024) **The cell biology of HIV-1 latency and rebound** *Retrovirology* **21**:6 <https://doi.org/10.1186/s12977-024-00639-w>

Nixon C. C., Mavigner M., Sampey G. C., Brooks A. D., Spagnuolo R. A., Irlbeck D. M., Mattingly C., Ho P. T., Schoof N., Cammon C. G., Tharp G. K., Kanke M., Wang Z., Cleary R. A., Upadhyay A. A., De C., Wills S. R., Falcinelli S. D., Galardi C., ..., Garcia J. V. (2020) **Systemic HIV and SIV latency reversal via non-canonical NF-kappaB signalling in vivo** *Nature* **578**:160–165 <https://doi.org/10.1038/s41586-020-1951-3>

Offley S. R., Pfleiderer M. M., Zucco A., Fraudeau A., Welsh S. A., Razew M., Galej W. P., Gardini A. (2023) **A combinatorial approach to uncover an additional Integrator subunit** *Cell Rep* **42**:112244 <https://doi.org/10.1016/j.celrep.2023.112244>

Pache L., Marsden M. D., Teriete P., Portillo A. J., Heimann D., Kim J. T., Soliman M. S. A., Dimapasoc M., Carmona C., Celeridad M., Spivak A. M., Planelles V., Cosford N. D. P., Zack J. A., Chanda S. K. (2020) **Pharmacological Activation of Non-canonical NF-kappaB Signaling Activates Latent HIV-1 Reservoirs In Vivo** *Cell Rep Med* **1**:100037 <https://doi.org/10.1016/j.xcrm.2020.100037>

- Ping Y. H., Rana T. M. (2001) **DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation** *J Biol Chem* **276**:12951–12958 <https://doi.org/10.1074/jbc.M006130200>
- Replogle J. M., Saunders R. A., Pogson A. N., Hussmann J. A., Lenail A., Guna A., Mascibroda L., Wagner E. J., Adelman K., Lithwick-Yanai G., Iremadze N., Oberstrass F., Lipson D., Bonnar J. L., Jost M., Norman T. M., Weissman J. S. (2022) **Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq** *Cell* **185**:2559–2575 <https://doi.org/10.1016/j.cell.2022.05.013>
- Rienzo M., Casamassimi A. (2016) **Integrator complex and transcription regulation: Recent findings and pathophysiology** *Biochim Biophys Acta* **1859**:1269–1280 <https://doi.org/10.1016/j.bbagr.2016.07.008>
- Rodari A., Darcis G., Van Lint C. M. (2021) **The Current Status of Latency Reversing Agents for HIV-1 Remission** *Annu Rev Virol* **8**:491–514 <https://doi.org/10.1146/annurev-virology-091919-103029>
- Schroder S., Cho S., Zeng L., Zhang Q., Kaehlcke K., Mak L., Lau J., Bisgrove D., Schnolzer M., Verdin E., Zhou M. M., Ott M. (2012) **Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes** *J Biol Chem* **287**:1090–1099 <https://doi.org/10.1074/jbc.M111.282855>
- Siliciano J. D., Siliciano R. F. (2024) **HIV cure: The daunting scale of the problem** *Science* **383**:703–705 <https://doi.org/10.1126/science.adk1831>
- Singh V., Dashti A., Mavigner M., Chahroudi A. (2021) **Latency Reversal 2.0: Giving the Immune System a Seat at the Table** *Curr HIV/AIDS Rep* **18**:117–127 <https://doi.org/10.1007/s11904-020-00540-z>
- Skaar J. R., Ferris A. L., Wu X., Saraf A., Khanna K. K., Florens L., Washburn M. P., Hughes S. H., Pagano M. (2015) **The Integrator complex controls the termination of transcription at diverse classes of gene targets** *Cell Res* **25**:288–305 <https://doi.org/10.1038/cr.2015.19>
- Spina C. A., Anderson J., Archin N. M., Bosque A., Chan J., Famiglietti M., Greene W. C., Kashuba A., Lewin S. R., Margolis D. M., Mau M., Ruelas D., Saleh S., Shirakawa K., Siliciano R. F., Singhania A., Soto P. C., Terry V. H., Verdin E., ..., Planelles V. (2013) **An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients** *PLoS Pathog* **9**:e1003834 <https://doi.org/10.1371/journal.ppat.1003834>
- Stadelmayer B., Micas G., Gamot A., Martin P., Malirat N., Koval S., Raffel R., Sobhian B., Severac D., Rialle S., Parrinello H., Cuvier O., Benkirane M. (2014) **Integrator complex regulates NELF-mediated RNA polymerase II pause/release and processivity at coding genes** *Nat Commun* **5**:5531 <https://doi.org/10.1038/ncomms6531>
- Stoszko M., Ne E., Abner E., Mahmoudi T. (2019) **A broad drug arsenal to attack a strenuous latent HIV reservoir** *Curr Opin Virol* **38**:37–53 <https://doi.org/10.1016/j.coviro.2019.06.001>
- Straining R., Eighmy W. (2022) **Tazemetostat: EZH2 Inhibitor** *J Adv Pract Oncol* **13**:158–163 <https://doi.org/10.6004/jadpro.2022.13.2.7>

- Tatomer D. C., Elrod N. D., Liang D., Xiao M. S., Jiang J. Z., Jonathan M., Huang K. L., Wagner E. J., Cherry S., Wilusz J. E. (2019) **The Integrator complex cleaves nascent mRNAs to attenuate transcription** *Genes Dev* **33**:1525–1538 <https://doi.org/10.1101/gad.330167.119>
- Telwatte S., Moron-Lopez S., Aran D., Kim P., Hsieh C., Joshi S., Montano M., Greene W. C., Butte A. J., Wong J. K., Yukl S. A. (2019) **Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency** *Retrovirology* **16**:32 <https://doi.org/10.1186/s12977-019-0494-x>
- Turner A. W., Bashore F. M., Falcinelli S. D., Fox J. A., Keller A. L., Fenton A. D., Geyer R. F., Allard B., Kirchherr J. L., Archin N. M., James L. I., Margolis D. M. (2024) **BET Degraders Reveal BRD4 Disruption of 7SK and P-TEFb is Critical for Effective Reactivation of Latent HIV in CD4+ T-cells** *bioRxiv* <https://doi.org/10.1101/2024.02.23.581756>
- Vermeire J., Naessens E., Vanderstraeten H., Landi A., Iannucci V., Van Nuffel A., Taghon T., Pizzato M., Verhasselt B. (2012) **Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti-and retroviral vectors** *PLoS One* **7**:e50859 <https://doi.org/10.1371/journal.pone.0050859>
- Welsh S. A., Gardini A. (2023) **Genomic regulation of transcription and RNA processing by the multitasking Integrator complex** *Nat Rev Mol Cell Biol* **24**:204–220 <https://doi.org/10.1038/s41580-022-00534-2>
- Yang Z., Yik J. H., Chen R., He N., Jang M. K., Ozato K., Zhou Q. (2005) **Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4** *Mol Cell* **19**:535–545 <https://doi.org/10.1016/j.molcel.2005.06.029>
- Yue J., Lai F., Beckedorff F., Zhang A., Pastori C., Shiekhatar R. (2017) **Integrator orchestrates RAS/ERK1/2 signaling transcriptional programs** *Genes Dev* **31**:1809–1820 <https://doi.org/10.1101/gad.301697.117>

Author information

Carley N Gray

Department of Microbiology, University of Washington, Seattle, United States
ORCID iD: [0009-0008-5173-2769](https://orcid.org/0009-0008-5173-2769)

Manickam Ashokkumar

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States, UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, United States
ORCID iD: [0000-0002-7880-9497](https://orcid.org/0000-0002-7880-9497)

Derek H Janssens[#]

Division of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, United States
ORCID iD: [0000-0003-1079-9525](https://orcid.org/0000-0003-1079-9525)

[#]Present address: Department of Epigenetics, Van Andel Institute, Grand Rapids, MI.

Jennifer Kirchherr

UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, United States

Brigitte Allard

UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, United States

Emily Hsieh

Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, United States

ORCID iD: [0000-0002-9415-9703](https://orcid.org/0000-0002-9415-9703)

Terry L Hafer

Division of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, United States, Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, United States

Nancie M Archin

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States, UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, United States

ORCID iD: [0000-0002-7938-0389](https://orcid.org/0000-0002-7938-0389)

Edward P Browne

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, United States, UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, United States

ORCID iD: [0000-0001-9070-7015](https://orcid.org/0000-0001-9070-7015)

Michael Emerman

Division of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, United States, Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, United States

ORCID iD: [0000-0002-4181-6335](https://orcid.org/0000-0002-4181-6335)

For correspondence: memerman@fredhutch.org

Editors

Reviewing Editor

Amit Singh

Indian Institute of Science, Bangalore, India

Senior Editor

John Schoggins

The University of Texas Southwestern Medical Center, Dallas, United States of America

Reviewer #1 (Public review):

Gray and colleagues describe the identification of Integrator complex subunit 12 (INTS12) as a contributor to HIV latency in two different cell lines and in cells isolated from the blood of people living with HIV. The authors employed a high-throughput CRISPR screening strategy to knock down genes and assess their relevance in maintaining HIV latency. They had used a similar approach in two previous studies, finding genes required for latency reactivation or

genes preventing it and whose knockdown could enhance the latency-reactivating effect of the NF κ B activator AZD5582. This work builds on the latter approach by testing the ability of gene knockdowns to complement the latency-reactivating effects of AZD5582 in combination with the BET inhibitor I-BET151. This drug combination was selected because it has been previously shown to display synergistic effects on latency reactivation.

The finding that INTS12 may play a role in HIV latency is novel, and the effect of its knock down in inducing HIV transcription in primary cells, albeit in only a subset of donors, is intriguing.

In this revised version, the authors have included new data and clarifications which help strengthen their conclusions.

<https://doi.org/10.7554/eLife.103064.2.sa3>

Reviewer #2 (Public review):

Summary:

Identifying an important role for Integrator complex in repressing HIV transcription and suggesting that by targeting subunits of this complex specifically, INTS12, reversal of latency with and without latency reversal agents can be enhanced.

Strengths:

The strengths of the paper include the general strategy for screening targets that may activate HIV latency and the rigor of exploring the mechanism of INTS12 repression of HIV transcriptional elongation.

Weaknesses:

Minor point-there was an opportunity to examine a larger panel of latency reversal agents that reactivate by different mechanisms to determine whether INTS12 and transcriptional elongation are limiting for a broad spectrum of latency reversal agents.

Comments on revisions:

I feel the authors have adequately addressed the original questions and concerns.

<https://doi.org/10.7554/eLife.103064.2.sa2>

Reviewer #3 (Public review):

Summary:

Transcriptionally silent HIV-1 genomes integrated in the host's genome represent the main obstacle for an HIV-1 cure. Therefore, agents aimed at promoting HIV transcription, the so-called latency reactivating agents (LRAs) might represent useful tools to render these hidden proviruses visible to the immune system. The authors successfully identified, through multiple techniques, INTS12, a component of the Integrator complex involved in 3' processing of small nuclear RNAs U1 and U2, as a factor promoting HIV-1 latency and hindering elongation of the HIV RNA transcripts. This factor hinders the activity of a previously identified combination of LRAs, one of which, AZD5582, has been validated in the macaque model for HIV persistence during therapy (<https://pubmed.ncbi.nlm.nih.gov/37783968/>). The other compound, I-BET151, is known to synergize with AZD5582, and is an inhibitor of BET,

factors counteracting elongation of RNA transcripts.
Therefore, INTS12 might represent a target for future LRAs-

Strengths:

Findings were confirmed through multiple screens and multiple techniques. The authors successfully mapped the identified HIV silencing factor at the HIV promoter, Silencing of INTS12 increases the activity of small-molecule HIV latency-reversing agents such as the histone deacetylase inhibitor vorinostat. Knockdown of INTS12 does not induce toxic effects in the cells, thus rendering it a candidate a drug discovery campaign aimed at finding new agents for an HIV/AIDS cure.

Weaknesses:

A caveat is that the impact of INTS12 in diverse T cell functions or other in vivo functions is not yet known, but the authors acknowledge this in the revised discussion.

<https://doi.org/10.7554/eLife.103064.2.sa1>

Author response:

The following is the authors' response to the original reviews.

Public Reviews:

Reviewer #1 (Public review):

Gray and colleagues describe the identification of Integrator complex subunit 12 (INTS12) as a contributor to HIV latency in two different cell lines and in cells isolated from the blood of people living with HIV. The authors employed a high-throughput CRISPR screening strategy to knock down genes and assess their relevance in maintaining HIV latency. They had used a similar approach in two previous studies, finding genes required for latency reactivation or genes preventing it and whose knockdown could enhance the latency-reactivating effect of the NFκB activator AZD5582. This work builds on the latter approach by testing the ability of gene knockdowns to complement the latency-reactivating effects of AZD5582 in combination with the BET inhibitor I-BET151. This drug combination was selected because it has been previously shown to display synergistic effects on latency reactivation.

The finding that INTS12 may play a role in HIV latency is novel, and the effect of its knockdown in inducing HIV transcription in primary cells, albeit in only a subset of donors, is intriguing. However, there are some data and clarifications that would be important to include to complement the information provided in the current version of the manuscript.

We have now added the requested data and clarifications. In particular, we show that knockout of INTS12 has no effect on cell proliferation (new data added in Figure 2—figure supplement 3)), we clarify how the degree of knockout and the complementation were accomplished, we clarify the differences between the RNA-seq and the activation scores, and we have bolstered the claim that INTS12 affected transcription elongation by performing CUT&Tag on Ser2 phosphorylation of the C-terminal tail of RNAPII along the length of the provirus (new data added in Figure 5C) Please see detailed responses below.

Reviewer #2 (Public review):

Summary:

Identifying an important role for the Integrator complex in repressing HIV transcription and suggesting that by targeting subunits of this complex specifically, INTS12, reversal of latency with and without latency reversal agents can be enhanced.

Strengths:

The strengths of the paper include the general strategy for screening targets that may activate HIV latency and the rigor of exploring the mechanism of INTS12 repression of HIV transcriptional elongation. I found the mechanism of INTS12 interesting and maybe even the most impactful part of the findings.

Weaknesses:

I have two minor comments:

There was an opportunity to examine a larger panel of latency reversal agents that reactivate by different mechanisms to determine whether INTS12 and transcriptional elongation are limiting for a broad spectrum of latency reversal agents.

I felt the authors could have extended their discussion of how exquisitely sensitive HIV transcription is to pausing and transcriptional elongation and the insights this provides about general HIV transcriptional regulation.

We have now added data on latency reversal agents of different mechanisms of action. We show that INTS12 affects HIV latency reversal from agents that affect the non-canonical NF- κ B pathway (AZD5582), the canonical NF- κ B pathway (TNF- α), activation via the T-cell receptor (CD3/CD28 antibodies), through bromodomain inhibition (I-BET151), and through a histone deacetylase inhibitor (SAHA). This additional data has been added to the manuscript in Figure 7, panels B and C as well as adding text to the discussion.

We appreciate the suggestion to extend the discussion to emphasize how important pausing and elongation are to HIV transcription. Additionally, to further support our claim that INTS12KO with AZD5582 & I-BET151 leads to an increase in elongation, that we previously showed with CUT&Tag data showing an increase in total RNAPII seen in within HIV (Figure 5B), we measured RNAPII Ser2 phosphorylation (Figure 5C) and RNAPII Ser5 phosphorylation (Figure 5—figure supplement 2) and added these findings to the manuscript. Upon measuring Ser2 phosphorylation, a marker associated with elongation, we observed evidence of elongation-competent RNAPII in our AZD5582 & I-BET151 condition as well as our INTS12 KO with AZD5582 & I-BET151 condition, as we saw an increase of Ser2 phosphorylation within HIV. Despite seeing elongation-competent RNAPII in both conditions, we only saw a dramatic increase in total RNAPII for our INTS12 KO and AZD5582 & I-BET151 condition (Figure 5B), which supports that there are more elongation events and that an elongation block is overcome specifically with INTS12 KO paired with AZD5582 & I-BET151. This claim is further supported by our data showing an increase in virus in the supernatant only with the INTS12 KO with AZD5582 & I-BET151 condition in cells from PLWH (Figure 6C). We did not observe any statistically significant differences between RNAPII Ser5 phosphorylation, which might be expected as this mark is not associated with elongation (Figure 5—figure supplement 2).

Reviewer #3 (Public review):

Summary:

Transcriptionally silent HIV-1 genomes integrated into the host's genome represent the main obstacle to an HIV-1 cure. Therefore, agents aimed at promoting HIV transcription, the so-called latency reactivating agents (LRAs) might represent useful tools to render these hidden proviruses visible to the immune system. The authors successfully identified,

through multiple techniques, INTS12, a component of the Integrator complex involved in 3' processing of small nuclear RNAs U1 and U2, as a factor promoting HIV-1 latency and hindering elongation of the HIV RNA transcripts. This factor synergizes with a previously identified combination of LRAs, one of which, AZD5582, has been validated in the macaque model for HIV persistence during therapy (<https://pubmed.ncbi.nlm.nih.gov/37783968/>). The other compound, I-BET151, is known to synergize with AZD5582, and is a inhibitor of BET, factors counteracting the elongation of RNA transcripts.

Strengths:

The findings were confirmed through multiple screens and multiple techniques. The authors successfully mapped the identified HIV silencing factor at the HIV promoter.

Weaknesses:

(1) Initial bias:

In the choice of the genes comprised in the library, the authors readdress their previous paper (Hsieh et al.) where it is stated: "To specifically investigate host epigenetic regulators involved in the maintenance of HIV-1 latency, we generated a custom human epigenome specific sgRNA CRISPR library (HuEpi). This library contains sgRNAs targeting epigenome factors such as histones, histone binders (e.g., histone readers and chaperones), histone modifiers (e.g., histone writers and erasers), and general chromatin associated factors (e.g., RNA and DNA modifiers) (Fig 1B and 1C)".

From these figure panels, it clearly appears that the genes chosen are all belonging to the indicated pathways. While I have nothing to object to on the pertinence to HIV latency of the pathways selected, the authors should spend some words on the criteria followed to select these pathways. Other pathways involving epigenetic modifications and containing genes not represented in the indicated pathways may have been left apart.

(2) Dereplication:

From Figure 1 it appears that INTS12 alone reactivates HIV -1 from latency alone without any drug intervention as shown by the MACGeCK score of DMSO-alone controls. If INTS12 knockdown alone shows antilateness effects, why, then were they unable to identify it in their previous article (Hsieh et al., 2023)? The authors should include some words on the comparison of the results using DMSO alone with those of the previous screen that they conducted.

(3) Translational potential:

In order to propose a protein as a drug target, it is necessary to adhere to the "primum non nocere" principle in medicine. It is therefore fundamental to show the effects of INTS12 knockdown on cell viability/proliferation (and, advisably, T-cell activation). These data are not reported in the manuscript in its current form, and the authors are strongly encouraged to provide them.

Finally, as many readers may not be very familiar with the general principles behind CRISPR Cas9 screening techniques, I suggest addressing them in this excellent review: <https://pmc.ncbi.nlm.nih.gov/articles/PMC7479249/>.

(1) The CRISPR library used was more completely described in a previous publication (Hsieh et al, PLOS Pathogens, 2023). However, we now more explicitly refer the reader to information about the pathways targeted in the library. We also point out how initial hits in the library lead to finding genes outside of the starting library as in the follow-up screen in

Figure 7 where each of the members of the INT complex are interrogated even though only INTS12 was the only member in the initial library.

(2) We understand the confusion between the hits in this paper and a previous publication. Indeed, INTS12 was observed in Hsieh et al., PLOS Pathogens, 2023 as a hit in the Venn diagram of Figure 3B of that paper, and in Figure 5A, right panel of that paper. However, it was not followed up on in the previous paper since that paper focused on a hit that was unique to increasing the potency of one particular LRA. We added text to the present manuscript to make it clear that the screens identified many of the same hits. We have also added additional data here on hit validation to underscore the reliability of the CRISPR screen. In one of the cell lines (5A8), EZH2 was a strong hit (Figure 1B). We have now added data that shows that an inhibitor to EZH2 augments the latency reversal of AZD5582/I-BET151 as predicted from the screen. This data has been added to Figure 1, figure supplement 1.

(3) We appreciate the concern that for INTS12 to be a drug target, it should not be essential to cell viability. We now show that knockout of INTS12 has no effect on cell proliferation (new data added in Figure 2—figure supplement 3). In addition, the discussion now adds additional literature references that describe how knockout of INTS12 has relatively minor effects on cell functions in comparison to knockout of other INT members which supports that the proposal that modulation of INTS12 may be more specific than targeting the catalytic modules of Integrator. Nonetheless, we completely agree with the reviewer that many other aspects of how INTS12 affects T cell functions have not been addressed as well as other potential detrimental effect of INTS12 as a drug target in vivo. We now more explicitly describe these caveats in the discussion but feel that the present manuscript is a first step with a long path ahead before the translational potential might be realized.

(4) We now cite the review of CRISPR screens suggested by the reviewer.

Responses to recommendations for the authors:

Reviewer #1 (Recommendations for the authors):

(1) The authors report in the legend of Figure 2 (and similarly in other figures) that there was "a calculated INTS12 knockout score of 76% (for the one guide used) and 69% (for one of three guides used), respectively." However, it would be helpful to show representative data on the efficiency of INTS12 knockdown in cell lines and primary cells, as well as data on the efficiency of the complementation (Figure 2C).

The knockout scores cited are the genetic assays for the efficiency based on sequence files. As the knockouts are done with multiple guides the knockout for each guide is an underestimate of the total knockout. The complementation, however, was done by adding back INTS12 in a lentiviral vector that also contains a drug resistance marker (puromycin). Cells were then selected for puromycin resistance, and therefore, all of them contain the complemented gene. What one would ideally like is a Western blot to quantify the amount of INTS12 remaining in the knockout pools. Unfortunately, despite obtaining multiple different commercial sources of INTS12 antibodies, we were unable to identify one that was suitable for Western blotting (as opposed to two that did work for CUT&Tag). Nonetheless, the functional data in primary T cells from PLWH and in J-Lat cells lines does show the even if the knockout is suboptimal, we find activation after INTS12 knockout (e.g., Figure 6).

(2) Flow cytometry methods are not reported, but was a viability dye included when testing GFP reactivation (Figure S2)? More broadly, showing data on the viability of cells post-knockdown and drug treatments would help, as cell mortality is inherently associated with latency reactivation in J-Lat cells. For the same reason, reporting viability data would be important for primary cells, as the electroporation procedure can lead to significant mortality.

We did not include viability dyes in the data for GFP activation. However, as described in the public response, we have done growth curves in J-Lat 10.6 cells with and without INTS12 knockout and find no effects on cell proliferation (Figure 2—figure supplement 3). As the reviewer points out, it is not possible to do these experiments in primary cells since the electroporation itself causes a degree of cell death. Nonetheless, we do see effects on HIV activation in these primary cells (Figure 6).

(3) Figure S2 shows a relatively high baseline expression (approximately 15%) of HIV-GFP, which is not unusual for the J-Lat 10.6 clone. However, Figure 3 appears to show no HIV RNA reads in the control condition of this same cell clone. How do the authors reconcile this discrepancy?

We believe that the discrepancies in the flow cytometry versus RNA-seq assays are due to differences in the sensitivity of the assays, the linear range of the assays especially at the lower end, and the different half-lives of RNA versus protein. We now clarify that Figure 3 does not show “no” HIV RNA at baseline, but rather values of ~30 copies per million read counts. This increases to ~800 copies per million read counts when INTS12 knockout cells are treated with AZD5582/I-BET151. These values have the same fold change predicted in Figure 4, and more closely resemble the trend in Figure 2—figure supplement 1.

(4) The combination of AZD5582 and I-BET151 consistently reactivates HIV latency (including GFP protein expression), as previously reported and as shown here by the authors. However, in Figure 5B, RPB3/RNAPII occupancy in the DMSO control appears higher than in the AAVS1KO + AZD5582 and I-BET151 samples. This should be discussed, as it could raise concerns about the robustness of RPB3/RNAPII occupancy results as a proxy for provirus elongation.

As addressed in the public comments, in order to strengthen our claims about transcriptional elongation control, we measured RNAPII Ser2 and Ser5 phosphorylation levels. We see evidence of elongation with Ser2 in the condition of concern (AAVS1 KO + AZD5582 & I-BET151) as well as our main condition of interest (INTS12 KO + AZD5582 & I-BET151) and no change in Ser5 for any condition. With both the Ser2 phosphorylation and total RNAPII as well as our virus release and transcription data we believe that we are seeing evidence of increased elongation with INTS12 KO with AZD5582 & I-BET151. One potential nuance that may not be gathered from the CUT&Tag data is the turnover rate of the polymerase. Despite the levels of RNAPII appearing lower in the condition of concern (AAVS1 KO + AZD5582 & I-BET151) compared to DMSO it is possible that low levels of elongation are occurring but that in our INTS12 KO + AZD5582 & I-BET151 condition there is more rapid elongation and this is why we can observe more RNAPII within HIV. This new data is added in Figure 5C and Figure 5—supplement 2 and its implications are now described in more detail in the discussion.

(5) The authors write that “Degree of reactivation was correlated with reservoir size as donors PH504 (star symbol) and PH543 (upside down triangle) have the largest HIV reservoirs (supplemental Figure S2).” I could not find mention of the reservoir size of these donors in the figure provided.

This confusion was caused by mislabeling of the supplement number, which we fixed, and we added additional labeling to make finding the reservoir size even more clear as this is an important part of the manuscript. This is now found in Supplemental file S4.

Reviewer #3 (Recommendations for the authors):

(1) The MAGeCK gene score is a feature that is essential for the interpretation of the results in Figure 1. The authors do quote the Li et al. paper where this score was

described for the first time (<https://genomebiology.biomedcentral.com/articles/10.1186/s13059-014-0554-4>), however, they may understand that not all readers may be familiar with this score. Therefore a didactic short description of this score should be done when introducing the results in Figure 1.

We have added a short description to the paper to address this.

(2) Figure 4. The authors write: "Among the host genes most prominently affected by INTS12 knockout with AZD5582 & I-BET151 are MAFA, MAFB, and ID2 (full list of genes in supplemental file S3)." I am a bit confused. In the linked Excel file there is only a list of a few genes. The differentially expressed genes appear to be many more from Figure 4. The full list should be uploaded.

We believe there was a mistake in our original uploading and naming of the supplements. We have now double-checked numbering on the supplements and added in text clarification of which excel tabs hold the desired information.

(3) Figure 6: The authors are right in highlighting that there is a high level of variability in viral RNA in supernatants in the early stages of viral reactivation. It is therefore advisable to repeat measurements at Day 7, at which variability decreases and data are more reliable (please, see: [https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964\(23\)00443-7/fulltext](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00443-7/fulltext)).

While it would have been nice to prolong these measurements, our current assay conditions are not optimal for longer term growth of the cells. We note that the measurements were all done in biological triplicates (independent knockouts) and in different individuals. Because the number of activatable latent proviruses is variable and the number of cells tested is limiting, the variability in the assays is expected.

(4) Figure 7: The main genes outside the INTS family should be identified, also.

We include the full list in supplemental file S5 and sort by most enriched.

(5) Methods: A statistical paragraph should be added in the Methods section, detailing the data analysis procedures and the key parameters utilized (for example, which is the MAGeCK gene score threshold that they used to consider knockdown efficacy on HIV latency?).

There is no MAGeCK score threshold that we use to determine efficacy on HIV latency. In a previous publication using CRISPR screens for HIV Dependency Factors (Montoya et al, mBio 2023), we showed that there is a relationship between the MAGeCK and the effect of that gene knockout on HIV replication (Figure 5 that paper). However, it is a continuum rather than a strict threshold and we believe that the effects on HIV latency would respond similarly. In the current paper, we have focused on the top hits rather than a comprehensive analysis of all the entire list. In case the reviewer is referring to the average and standard deviation of the non-targeting controls, we have added this to the figure legend and methods.

<https://doi.org/10.7554/eLife.103064.2.sa0>